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PREFACE
In 1995, the U.S. Public Health Service (USPHS) and the Infectious Diseases Society
of America (IDSA) developed guidelines for preventing opportunistic infections (OIs)
in persons infected with human immunodeficiency virus (HIV) (1-3). These guide-
lines, written for health-care providers and patients, were revised in 1997 and
published in the MMWR (4), Cfinical Infectious Diseases (5), the Annals of Internal
Medicine (6), the American Family Physician (7), and Pediatrics (8); an accompany-
ing editorial appeared in JAMA (9). Response to these guidelines (e.g., the many
requests for reprints and observations from health-care providers) suggests they have
served as a valuable reference for HIV care providers. Because the 1995 and 1997
guidelines included ratings indicating the strength of each recommendation and the
quality of supporting evidence, readers were able to assess the relative importance of
each recommendation.
Since AIDS was first recognized nearly 20 years ago, remarkable progress has been
made in improving the quality and duration of life of HIV-infected persons. During the
first decade of the epidemic, this improvement occurred because of better recognition
of opportunistic disease processes, better therapy for acute and chronic complica-
tions, and the introduction of chemoprophylaxis against Pneumocystis carinii
pneumonia (PCP), toxoplasmosis, Mycobacterium avium complex disease, and bacte-
rial infections. Trimethoprim-sulfamethoxazole was shown to reduce not only the
incidence of PCP but also of toxoplasmosis and bacterial infections.
The second decade of the epidemic has witnessed extraordinary progress in devel-
oping highly active antiretroviral therapies (HAART) as well as continuing progress in
preventing and treating individual OIs. HAART has reduced the incidence of OIs and
extended life substantially 10 ). HAART is the most effective approach to preventing
OIs and should be considered for all HIV-infected persons who qualify for such ther-
apy. However, some patients are not ready or able to take HAART, and others have
tried HAART regimens, but therapy has failed. Such patients will benefit from prophy-
laxis against OIs. In addition, prophylaxis against specific OIs continues to provide
survival benefits even among persons who are receiving HAART 11 ).
Because important new data concerning the prevention of opportunistic diseases
have emerged since 1997, the USPHS and the IDSA reconvened the Prevention of
Opportunistic Infections Working Group on March 4 and 5, 1999, to determine which
recommendations warranted revision. Participants included representatives from
federal a.qencies, universities, and professional societies, as well as community
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health-care providers and patient advocates. Much attention was focused on recent
data related to the advisability of discontinuing OI prophylaxis (primary prophylaxis
and prophylaxis against recurrence) among persons whose CD4+ T-lymphocyte
counts have increased to above prophylaxis thresholds because of HAART. The
OI Working Group also addressed two pathogens not previously considered human
herpesvirus type 8 and hepatitis C virus. In addition, working group members
reviewed data concerning the prevention of all common HIV-associated OIs. In revis-
ing these current guidelines, as in earlier editions of the guidelines, the group
considered factors such as incidence of disease; severity of disease in terms of mor-
bidity and mortality; level of immunosuppression at which disease is most likely to
occur; feasibility, efficacy, and cost of preventive measures; impact of intervention on
quality of life; and drug toxicities, drug interactions, and the potential for drug resis-
tance to develop.
During the development of these revised guidelines, working group members
reviewed published manuscripts as well as abstracts and material presented at pro-
fessional meetings if complete manuscripts providing data were available for review.
A review of the data that served as the basis for the revisions and additional informa-
tion discussed at the meeting but not deemed sufficient to justify a revision of the
recommendations will be published separately in Clinical Infectious Diseases.
Primary Changes in the Recommendations
Primary changes in the disease-specific recommendations that follow include
= The addition of statements concerning discontinuation of prophylaxis against
specific OIs when the CD4+ T-lymphocyte count increases in response to HAART.
New recommendations regarding human herpesvirus type 8 and hepatitis C
virus.
New recommendations concerning injection drug users.
New recommendations about short-course chemoprophylaxis against tuberculo-
sis in HIV-infected persons with positive tuberculin skin tests.
Changes in secondary prophylaxis (chronic maintenance therapy) recommended
to prevent the recurrence of Mycobacterium avium complex and cytomega-
Iovirus disease.
Caution against using fluconazole during pregnancy.
Statements concerning the use of varicella and rotavirus vaccines among HIV-
infected infants.
These guidelines developed by the OI Working Group were made available for pub-
lic comment through announcements in the Federal Register and the MMWR. The
final document is endorsed by the USPHS and IDSA as well as by the Infectious
Diseases Society of Obstetrics and Gynecology and the National Foundation for
Infectious Diseases.
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How to Use the Information in This Report
For each of the 19 diseases covered in this report, specific recommendations are
provided that address a) prevention of exposure to the opportunistic pathogen, b) pre-
vention of the first episode of disease, and c) prevention of disease recurrence.
Recommendations are rated by a revised version of the IDSA rating system (see Box)
72 ). In this system, the letters A through E signify the strength of the recommenda-
tion for or against a preventive modality, and Roman numerals through III indicate
the quality of evidence supporting the recommendation.
Because of their length and complexity, the tables in this report are grouped
together, following the references. The tables appear in the following order: dosages
for prophylaxis to prevent first episode of opportunistic disease in HIV-infected adults
System used to rate the strength of recommendations and quality of supporting
evidence*
Rating
A
C
Strength of the recommendation
Both strong evidence for efficacy and substantial clinical bene-
fit support recommendation for use. Should always be offered.
Moderate evidence for efficacy- or strong evidence for effi-
cacy but only limited clinical benefit--supports recommenda-
tion for use. Should generally be offered.
Evidence for efficacy is insufficient to support a recommenda-
tion for or against use. Or evidence for efficacy might not
outweigh adverse consequences (e.g., drug toxicity, drug inter-
actions) or cost of the chemoprophylaxis or alternative
approaches. Optional.
Moderate evidence for lack of efficacy or for adverse outcome
supports a recommendation against use. Should generally not
be offered.
Good evidence for lack of efficacy or for adverse outcome sup-
ports a recommendation against use. Should never be offered.
III
Quality of evidence supporting the recommendation
Evidence from at least one properly randomized, controlled
trial.
Evidence from at least one well-designed clinical trial without
randomization, from cohort or case-controlled analytic studies
(preferably from more than one center), or from multiple time-
series studies. Or dramatic results from uncontrolled experi-
ments.
Evidence from opinions of respected authorities based on
clinical experience, descriptive studies, or reports of expert
committees.
* Modified from Gross PA, Barrett TL, Dellinger EP, et al., 1994 (12).
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and adolescents (Table 1); dosages for prophylaxis to prevent recurrence of opportun-
istic disease in HIV-infected adults and adolescents (Table 2); effects of food on drugs
used to treat OIs (Table 3); effects of medications on drugs used to treat OIs (Table 4);
effects of OI medications on drugs commonly administered to HIV-infected persons
(Table 5); adverse effects of drugs used to manage HIV infection (Table 6); dosages of
drugs for prevention of OIs for persons with renal insufficiency (Table 7); costs of
agents recommended for the prevention of OIs in adults with HIV infection (Table 8);
immunologic categories for HIV-infected children (Table 9); immunization schedule for
HIV-infected children (Table 10); dosages for prophylaxis to prevent first episode of
opportunistic disease in HIV-infected infants and children (Table 11); dosages for pro-
phylaxis to prevent recurrence of opportunistic disease in HIV-infected infants and
children (Table 12); and criteria for discontinuing and restarting OI prophylaxis for
adult patients with HIV infection (Table 13). Recommendations advising patients how
to prevent exposure to opportunistic pathogens appear in the appendix at the end of
this report.
This report is oriented toward the prevention of specific opportunistic infections
in HIV-infected persons in the United States and other industrialized countries. Rec-
ommendations for use of antiretroviral therapy, which is designed to prevent
immunologic deterioration and delay the need for many of the chemoprophylactic
strategies described in this report, are published elsewhere (10) as are integrated
approaches to the care of HIV-infected persons 13 ).
Single copies of this report can be obtained from the AIDS Treatment Information
Service (ATIS) by calling (800) 448-0440, (301) 217-0023 (international), or (800) 243-
7012 (TTY), and the report can be downloaded from the ATIS website at
<www.hivatis.org>. In addition, pamphlets for patients are available from ATIS and
also can be accessed on CDC’s Division of HIV/AIDS Prevention homepage at
<www.cdc.gov/hiv>.
New data on prevention of OIs in HIV-infected persons are emerging, and random-
ized controlled trials addressing some unresolved issues in OI prophylaxis are
ongoing. The OI Working Group has therefore developed a mechanism for routinely
and periodically reviewing emerging data and for updating these guidelines on a
regular basis. The most recent information will be available from the ATIS website at
<www.hivatis.org>.
DISEASE-SPECIFIC RECOMMENDATIONS
Pneumocystis carinfi Pneumonia
Prevention of Exposure
1. Although some authorities recommend that persons with human immunodefi-
ciency virus (HIV) infection who are at risk for R carinii pneumonia (PCP) not share a
hospital room with a patient who has PCP, data are insufficient to support this recom-
mendation as standard practice (Clil).
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Prevention ofDisease
Initiation of Primary Prophylaxis
2. Adults and adolescents who have HIV infection (including pregnant women and
those on HAART) should receive chemoprophylaxis against PCP if they have a CD4+ T-
lymphocyte count of <200/pL (AI) or a history of oropharyngeal candidiasis (All) 14 ).
Persons who have a CD4+ T-lymphocyte percentage of <14% or history of an acquired
immunodeficiency syndrome (AIDS)-defining illness but do not otherwise qualify
should be considered for prophylaxis (BII) (15,16). When monitoring the CD4+
T-lymphocyte count at least every 3 months is not possible, initiation of chemoprophy-
laxis at a CD4+ T-lymphocyte count of >200 but <250 cells/pL also should be
considered (BII) 15 ).
3. Trimethoprim-sulfamethoxazole (TMP-SMZ)is the recommended prophylactic
agent (AI) (16-18). One double-strength tablet per day is the preferred regimen (AI)
(17). However, one single-strength tablet per day (19) is also effective and might be
better tolerated (AI). One double-strength tablet three times per week is also effective
(BI) (20). TMP-SMZ at a dose of one double-strength tablet per day confers cross-pro-
tection against toxoplasmosis (21) and some common respiratory bacterial infections
(17,22). Lower doses of TMP-SMZ also might confer such protection. For patients
who have an adverse reaction that is not life-threatening, treatment with TMP-SMZ
should be continued if clinically feasible; for those who have discontinued such ther-
apy because of an adverse reaction, reinstitution of TMP-SMZ should be strongly
considered after the adverse event has resolved (All). Patients who have experienced
adverse events, especially fever and rash, might better tolerate reintroduction of the
drug with a gradual increase in dose (desensitization) as per published regimens (BI)
(23,24) or reintroduction of TMP-SMZ at a reduced dose or frequency (CIII); up to 70%
of patients can tolerate such reinstitution of therapy (22).
4. If TMP-SMZ cannot be tolerated, prophylactic regimens that can be recom-
mended as alternatives include dapsone (BI) (17), dapsone plus pyrimethamine plus
leucovorin (BI) (25,26), aerosolized pentamidine administered by the Respirgard II
nebulizer (Marquest, Englewood, Colorado) (BI) (18), and atovaquone (BI) (27,28).
Atovaquone appears to be as effective as aerosolized pentamidine (28) or dapsone
(BI) (27) but is substantially more expensive than the other regimens. For patients
seropositive for Toxoplasma gondii who cannot tolerate TMP-SMZ, recommended
alternatives to TMP-SMZ for prophylaxis against both PCP and toxoplasmosis include
dapsone plus pyrimethamine (BI)(25,26) or atovaquone with or without
pyrimethamine (CIII). The following regimens generally cannot be recommended as
alternatives because data regarding their efficacy for PCP prophylaxis are insufficient
for a firm recommendation: aerosolized pentamidine administered by other nebuliza-
tion devices, intermittently administered parenteral pentamidine, oral pyrimethamine
plus sulfadoxine, oral clindamycin plus primaquine, and intravenous trimetrexate.
However, clinicians may consider using these agents in unusual situations in Which
the recommended agents cannot be administered (CIII).
Discontinuation of Primary Prophylaxis
5. Initial reports from three prospective observational studies (29-31), one retro-
spective review (32), and one randomized trial (33) suggest that PCP prophylaxis can
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 91999 USPHS/IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS
be safely discontinued in patients responding to HAART with a sustained increase in
CD4+ T-lymphocyte counts from <200 cells/L to >200 cells/tL. Such reports have
mostly included patients receiving primary prophylaxis (no prior episode of PCP) and
protease inhibitor-containing regimens. In these studies, median follow-up ranged
from 6 to 12 months and the median CD4+ T-lymphocyte count at the time prophylaxis
was discontinued was >300 cell/tL. At the time PCP prophylaxis was discontinued,
many patients had sustained suppression of HIV plasma RNA levels below detection
limits of the available assays. Although optimal criteria for discontinuing PCP prophy-
laxis are still being assessed, providers may wish to discontinue prophylaxis when
patients have sustained a CD4+ T-lymphocyte count of >200 cells/tL for at least
3-6 months (CII). Additional criteria might include sustained reduction in viral load for
at least 3-6 months (CIII).
Restarting Primary Prophylaxis
6. No data are available to guide recommendations for reinstituting primary pro-
phylaxis. Pending the availability of such data, a reasonable approach would be to use
the criteria for initiating prophylaxis described on page 5 (CIII).
Prevention of Recurrence
7. Adults and adolescents who have a history of PCP should be administered
chemoprophylaxis (i.e., secondary prophylaxis or chronic maintenance therapy) with
the regimens described on page 5 in order to prevent recurrence (AI) 16 ).
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)
8. Although patients receiving secondary prophylaxis (prior episode of PCP) might
also be at low risk for PCP when their CD4+ T-lymphocyte counts increase to
>200 cells/tL, inadequate numbers of patients have been evaluated to warrant a
recommendation to discontinue prophylaxis in such patients.
Special Considerations
Children
9. Children born to HIV-infected mothers should be administered prophylaxis with
TMP-SMZ beginning at 4-6 weeks of age (34) (All). Prophylaxis should be discontin-
ued for children who are subsequently found not to be infected with HIV. HIV-infected
children and children whose infection status remains unknown should continue to
receive prophylaxis for the first year of life. The need for subsequent prophylaxis
should be determined on the basis of age-specific CD4+ T-lymphocyte count thresh-
olds (Table 11) (All). The safety of discontinuing prophylaxis in HIV-infected children
receiving HAART has not been studied.
10. Children who have a history of PCP should be administered lifelong chemopro-
phylaxis to prevent recurrence (AI) (34).
Pregnant Women
11. Chemoprophylaxis for PCP should be administered to pregnant women as is
done for other adults and adolescents (AIII). TMP-SMZ is the recommended prophy-
lactic agent; dapsone is an alternative. Because of theoretical concerns regarding
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possible teratogenicity associated with drug exposures during the first trimester,
providers may choose to withhold prophylaxis during the first trimester. In such cases,
aerosolized pentamidine may be considered because of its lack of systemic absorp-
tion and the resultant lack of exposure of the developing embryo to the drug (CIII).
Toxoplasmic Encephalitis
Prevention ofExposure
1. HIV-infected persons should be tested for immunoglobulin G (IgG) antibody to
Toxoplasma soon after the diagnosis of HIV infection to detect latent infection with
Toxoplasma gondii (Bill).
2. All HIV-infected persons, but particularly those who lack IgG antibody to
Toxoplasma, should be counseled about the various sources of toxoplasmic infection.
They should be advised not to eat raw or undercooked meat, particularly undercooked
pork, lamb, or venison (Bill). Specifically, meat should be cooked to an internal tem-
perature of 150 F (65.5 C); meat cooked until it is no longer pink inside generally has
an internal temperature of 165 F (73.8 C) and therefore satisfies this requirement. HIV-
infected persons should wash their hands after contact with raw meat and after
gardening or other contact with soil; in addition, they should wash fruits and vegeta-
bles well before eating them raw (Bill). If the patient owns a cat, the litter box should
be changed daily, preferably by an HIV-negative, nonpregnant person; alternatively,
the patient should wash the hands thoroughly after changing the litter box (Bill).
Patients should be encouraged to keep their cats inside and not to adopt or handle
stray cats (Bill). Cats should be fed only canned or dried commercial food or well-
cooked table food, not raw or undercooked meats (Bill). Patients need not be advised
to part with their cats or to have their cats tested for toxoplasmosis (Ell).
Prevention of Disease
Initiation of Primary Prophylaxis
3. Toxoplasma-seropositive patients who have a CD4+ T-lymphocyte count of
<100/pL should be administered prophylaxis against toxoplasmic encephalitis (TE)
(All) (21). The double-strength tablet daily dose of TMP-SMZ recommended as the
preferred regimen for PCP prophylaxis appears to be effective against TE as well and
is therefore recommended (All) (21 ). If patients cannot tolerate TMP-SMZ, the recom-
mended alternative is dapsone-pyrimethamine, which is also effective against PCP
(BI) (25,26). Atovaquone with or without pyrimethamine also may be considered
(CIII). Prophylactic monotherapy with dapsone, pyrimethamine, azithromycin, or
clarithromycin cannot be recommended on the basis of current data (DII). Aerosolized
pentamidine does not protect against TE and is not recommended (El) (17,21).
4. Toxoplasma-seronegative persons who are not taking a PCP prophylactic regi-
men known to be active against TE should be retested for IgG antibody to Toxoplasma
when their CD4+ T-lymphocyte count declines below 100/pL to determine whether
they have seroconverted and are therefore at risk for TE (CIII). Patients who have sero-
converted should be administered prophylaxis for TE as described above (All).
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Discontinuation of Primary Prophylaxis
5. Limited data suggest that discontinuing prophylaxis for patients whose CD4+
T-lymphocyte counts increase to >100 cells/tL in response to HAART is associated
with a low risk for TE. However, the numbers of patients who have been evaluated are
insufficient to recommend routine discontinuation of prophylaxis in such patients.
Persons whose CD4+ T-lymphocyte count remains <200 cells/tL or who have a history
of PCP or oropharyngeal candidiasis still require prophylaxis against PCP, as noted
previously.
Prevention ofRecurrence
6. Patients who have had TE should be administered lifelong suppressive therapy
(secondary prophylaxis or chronic maintenance therapy) with drugs active against
Toxoplasma to prevent relapse (AI) (35,36). The combination of pyrimethamine plus
sulfadiazine and leucovorin is highly effective for this purpose (AI) (35,36). A com-
monly used regimen for patients who cannot tolerate sulfa drugs is pyrimethamine
plus clindamycin (BI); however, only the combination of pyrimethamine plus sul-
fadiazine appears to provide protection, against PCP as well (All).
Discontinuation ofSecondary Prophylaxis (Chronic Maintenance Therapy)
7. The numbers of patients who have stopped maintenance therapy after respond-
ing to HAART are insufficient to warrant recommending discontinuation of main-
tenance therapy.
Special Considerations
Children
8. TMP-SMZ, when administered for PCP prophylaxis, also provides prophylaxis
against toxoplasmosis. Atovaquone might also provide protection (CIII). Children
aged >12 months who qualify for PCP prophylaxis and who are receiving an agent
other than TMP-SMZ or atovaquone should have serologic testing for Toxoplasma
antibody (Bill), because alternative drugs for PCP prophylaxis might not be effective
against Toxoplasma. Severely immunosuppressed children who are not receiving
TMP-SMZ or atovaquone who are found to be seropositive for Toxoplasma should be
administered prophylaxis for both PCP and toxoplasmosis (i.e., dapsone plus
pyrimethamine) (Bill).
Pregnant Women
9. TMP-SMZ can be administered for prophylaxis against TE as described for
PCP (AIII). However, because of the low incidence of TE during pregnancy and the
possible risk associated with pyrimethamine treatment, chemoprophylaxis with
pyrimethamine-containing regimens can reasonably be deferred until after pregnancy
(CIII). For prophylaxis against recurrent TE, the health-care provider and clinician
should be well informed about the benefit of lifelong therapy and the concerns about
teratogenicity of pyrimethamine. Most clinicians favor lifelong therapy for the mother,
given the high likelihood that disease will recur promptly if therapy is stopped (AIII).
12 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY1999 USPHS/IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS
10. In rare cases, HIV-infected pregnant women who have serologic evidence of
remote toxoplasmic infection have transmitted Toxoplasma to the fetus in utero. Preg-
nant HIV-infected women who have evidence of primary toxoplasmic infection or
active toxoplasmosis (including TE) should be evaluated and managed during preg-
nancy in consultation with appropriate specialists (Bill). Infants born to women who
have serologic evidence of infections with HIV and Toxoplasma should be evaluated
for congenital toxoplasmosis (Bill).
Cryptosporidiosis
Prevention ofExposure
1. HIV-infected persons should be educated and counseled about the many ways
that Cryptosporidium can be transmitted (Bill). Modes of transmission include having
direct contact with infected adults, diaper-aged children, and infected animals; drink-
ing contaminated water; coming into contact with contaminated water during
recreational activities; and eating contaminated food.
2. HIV-infected persons should avoid contact with human and animal feces. They
should be advised to wash their hands after contact with human feces (e.g., diaper
changing), after handling pets, and after gardening or other contact with soil. HIV-
infected persons should avoid sexual practices that might result in oral exposure to
feces (e.g., oral-anal contact) (Bill).
3. HIV-infected persons should be advised that newborn and very young pets might
pose a small risk for transmitting cryptosporidial infection, but they should not be
advised to destroy or give away healthy pets. Persons contemplating the acquisition
of a new pet should avoid bringing any animal that has diarrhea into their households,
should avoid purchasing a dog or cat aged <6 months, and should not adopt stray
pets. HIV-infected persons who wish to assume the small risk for acquiring a puppy or
kitten aged <6 months should request that their veterinarian examine the animal’s
stool for Cryptosporidium before they have contact with the animal (Bill).
4. HIV-infected persons should avoid exposure to calves and lambs and to premises
where these animals are raised (BII).
5. HIV-infected persons should not drink water directly from lakes or rivers (AIII).
6. Waterborne infection also might result from swallowing water during recrea-
tional activities. HIV-infected persons should be aware that many lakes, rivers, and
salt-water beaches and some swimming pools, recreational water parks, and orna-
mental water fountains might be contaminated with human or animal waste that
contains Cryptosporidium. They should avoid swimming in water that is likely to
be contaminated and should avoid swallowing water while swimming or playing in
recreational waters (Bill).
7. Several outbreaks of cryptosporidiosis have been linked to municipal water sup-
plies. During outbreaks or in other situations in which a community "boil-water"
advisory is issued, boiling water for 1 minute will eliminate the risk for crypto-
sporidiosis (AI). Use of submicron personal-use water filters* (home/office types)
*Only filters capable of removing particles m in diameter should be considered. Filters that
provide the greatest assurance of oocyst removal include those that operate by reverse
osmosis, those labeled as absolute 1-tm filters, and those labeled as meeting NSF (National
Sanitation Foundation) standard no. 53 for cyst removal. The nominal 1-tm filter rating is not
standardized, and many filters in this category might not be capable of removing 99% of
oocysts.
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and/or bottled water also might reduce the risk (CIII). The magnitude of the risk for
acquiring cryptosporidiosis from drinking water in a nonoutbreak setting is uncertain,
and current data are inadequate to recommend that all HIV-infected persons boil
water or avoid drinking tap water in nonoutbreak settings. However, HIV-infected
persons who wish to take independent action to reduce the risk for waterborne crypto-
sporidiosis may choose to take precautions similar to those recommended during
outbreaks. Such decisions should be made in conjunction with health-care providers.
Persons who opt for a personal-use filter or bottled water should be aware of the com-
plexities involved in selecting appropriate products, the lack of enforceable standards
for the destruction or removal of oocysts, the cost of the products, and the logistic
difficulty of using these products consistently.
8. Patients who take precautions to avoid acquiring cryptosporidiosis from drinking
water should be advised that ice made from contaminated tap water also can be a
source of infection (BII). Such persons also should be aware that fountain beverages
served in restaurants, bars, theaters, and other places also might pose a risk because
these beverages, as well as the ice they contain, are made from tap water. Nationally
distributed brands of bottled or canned carbonated soft drinks are safe to drink. Com-
mercially packaged noncarbonated soft drinks and fruit juices that do not require
refrigeration until after they are opened (i.e., those that can be stored unrefrigerated
on grocery shelves) also are safe. Nationally distributed brands of frozen fruit juice
concentrate are safe if they are reconstituted by the user with water from a safe
source. Fruit juices that must be kept refrigerated from the time they are processed to
the time of consumption might be either fresh (unpasteurized) or heat-treated (pas-
teurized); only those juices labeled as pasteurized should be considered free of risk
from Cryptosporidium. Other pasteurized beverages and beers also are considered
safe to drink (BII). No data are available concerning survival of Cryptosporidium
oocysts in wine.
9. HIV-infected persons should avoid eating raw oysters because cryptosporidial
oocysts can survive in oysters for more than 2 months and have been found in oysters
taken from some commercial oyster beds (Bill). Cryptosporidium-infected patients
should not work as food handlers, especially if the food to be handled is intended
to be eaten without cooking (BII). Because most foodborne outbreaks of crypto-
sporidiosis are believed to have been caused by infected food handlers, more specific
recommendations to avoid exposure to contaminated food cannot be made.
10. In a hospital, standard precautions (i.e., use of gloves and hand washing after
removal of gloves) should be sufficient to prevent transmission of cryptosporidiosis
from an infected patient to a susceptible HIV-infected person (BII). However, because
of the potential for fomite transmission, some experts recommend that HIV-infected
persons, especially those who are severely immunocompromised, should not share a
room with a patient with cryptosporidiosis (CIII).
Sources of bottled water (e.g., wells, springs, municipal tap-water supplies, rivers, and lakes)
and methods for its disinfection differ; therefore, all brands should not be presumed to be
free of cryptosporidial oocysts. Water from wells and springs is much less likely to be con-
taminated by oocysts than water from rivers or lakes. Treatment of bottled water by distillation
or reverse osmosis ensures oocyst removal. Water passed through an absolute 1-m filter or
a filter labeled as meeting NSF standard no. 53 for cyst removal before bottling will provide
nearly the same level of protection. Use of nominal 1-Fm filters by bottlers as the only barrier
to Cr)/ptosporidia might not result in the removal of 99% of oocysts.
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Prevention of Disease
11. No agents have been proven to be effective as chemoprophylaxis against cryp-
tosporidiosis. Rifabutin or clarithromycin, when taken for Mycobacterium avium
complex prophylaxis, were associated with a reduced risk for cryptosporidiosis in one
study (37), but data are insufficient to warrant a recommendation for using these
drugs.
Prevention of Recurrence
12. No drug regimens are known to be effective in preventing the recurrence of
cryptospo rid osis.
Special Considerations
Children
13. At present, no data indicate that formula-preparation practices for infants
should be altered in an effort to prevent cryptosporidiosis (CIII). However, in the event
of a "boil-water" advisory, similar precautions for the preparation of infant formula
should be taken as for drinking water for adults (All).
IViicrosporidiosis
Prevention ofExposure
1. Other than general attention to hand washing and other personal hygiene meas-
ures, no precautions to reduce exposure can be recommended at this time.
Prevention of Disease
2. No chemoprophylactic regimens are known to be effective in preventing
rn icrosporidiosis.
Prevention of Recurrence
3. No chemotherapeutic regimens are known to be effective in preventing the
recurrence of microsporidiosis.
Tuberculosis
Prevention of Exposure
1. HIV-infected persons should be advised that certain activities and occupations
might increase the likelihood of exposure to tuberculosis (Bill). These include volun-
teer work or employment in health-care facilities, correctional institutions, and
shelters for the homeless, as well as in other settings identified as high risk by local
health authorities. Decisions about whether to continue with activities in these set-
tings should be made in conjunction with the health-care provider and should be
based on factors such as the patient’s specific duties in the workplace, the prevalence
of tuberculosis in the community, and the degree to which precautions are taken to
prevent the transmission of tuberculosis in the workplace (Bill). Whether the patient
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continues with such activities might affect the frequency with which screening for
tuberculosis needs to be conducted.
Prevention of Disease
2. When HIV infection is first recognized, the patient should receive a tuberculin
skin test (TST) by administration of intermediate-strength (5-TU) purified protein
derivative (PPD) by the Mantoux method (AI). Routine evaluation for anergy is not
recommended. However, there are selected situations in which anergy evaluation
might assist in guiding individual decisions about preventive therapy (38).
3. All HIV-infected persons who have a positive TST result (5 mm of induration)
should undergo chest radiography and clinical evaluation to rule out active tuberculo-
sis. HIV-infected persons who have symptoms suggestive of tuberculosis should
promptly undergo chest radiography and clinical evaluation regardless of their TST
status (All).
4. All HIV-infected persons, regardless of age, who have a positive TS.’I result yet
have no evidence of active tuberculosis and no history of treatment or prophylaxis for
tuberculosis should be administered preventive chemotherapy. Options include
isoniazid daily (All) or twice weekly (BI) for 9 months or 2 months of therapy with
either rifampin and pyrazinamide (AI) or rifabutin and pyrazinamide (Bill) (38).
Because HIV-infected persons are at risk for peripheral neuropathy, those receiving
isoniazid should also receive pyridoxine (Bill). A decision to use a regimen containing
either rifampin or rifabutin should be made after careful consideration of potential
drug interactions, especially those related to protease inhibitors and nonnucleoside
reverse transcriptase inhibitors (see Special Considerations/Drug Interactions, page
13). Directly observed therapy should be used with intermittent dosing regimens (AI)
and when otherwise operationally feasible (Bill) (38).
5. HIV-infected persons who are close contacts of persons who have infectious
tuberculosis should be administered preventive therapy regardless of their TST
results, age, or prior courses of chemoprophylaxis after the diagnosis of active
tuberculosis has been excluded (All) (38). In addition to household contacts, such per-
sons might also include contacts in the same drug-treatment or health-care facility,
coworkers, and other contacts if transmission of TB is demonstrated.
6. For persons exposed to isoniazid- and/or rifampin-resistant TB, the decision to
use chemoprophylactic antimycobacterial agents other than isoniazid alone, rifampin
plus pyrazinamide, or rifabutin plus pyrazinamide should be based on the relative risk
for exposure to resistant organisms and should be made in consultation with public
health authorities (All).
7. TST-negative, HIV-infected persons from risk groups or geographic areas with a
high prevalence of Mycobacterium tuberculosis infection might be at increased risk
for primary or reactivation tuberculosis. However, the efficacy of preventive therapy in
this group has not been demonstrated. Decisions concerning the use of chemopro-
phylaxis in these situations must be considered individually.
8. Although the reliability of the TST might diminish as the CD4+ T-lymphocyte
count declines, annual repeat testing should be considered for HIV-infected persons
who are TST-negative on initial evaluation and who belong to populations in which
there is a substantial risk for exposure to M. tuberculosis (Bill). Clinicians also may
consider repeating TSTs for persons whose immune function has improved because
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of HAART (i.e., those whose CD4+ T-lymphocyte count has increased to >200 cells/#L)
(CIII). In addition tO confirming tuberculous infection, TST conversion in an
HIV-infected person should alert health-care providers to the possibility of recent
M. tuberculosis transmission and should prompt notification of public health officials
for investigation to identify a possible source case.
9. The administration of bacille Calmette-Gurin (BCG) vaccine to HIV-infected per-
sons is contraindicated because of its potential to cause disseminated disease (Ell).
Prevention ofRecurrence
10. Chronic suppressive therapy for a patient who has successfully completed a
recommended regimen of treatment for tuberculosis is not necessary (DII).
Special Considerations
Drug Interactions
11. Rifampin should not be administered with protease inhibitors or nonnucleoside
reverse transcriptase inhibitors (El) (38). Rifabutin is an acceptable alternative but
should not be used with the protease inhibitor hard-gel saquinavir; caution is also
advised if the drug is coadministered with soft-gel saquinavir, but data are lacking.
Rifabutin can be administered at one half the usual daily dose (i.e., reduce from
300 mg to 150 mg per day) with indinavir, nelfinavir, or amprenavir or with one fourth
the usual dose (i.e., 150 mg every other day or three times a week) with ritonavir.
Similarly, rifabutin should not be used with the nonnucleoside reverse transcriptase
inhibitor delavirdine. Pharmacokinetic data suggest that rifabutin at an increased dose
can be administered with efavirenz; a dose of 450 mg per day has been suggested
(38). Information is lacking regarding coadministration of rifabutin with nevirapine.
Children
12. Infants born to HIV-infected mothers should have a TST (5-TU PPD) at or before
the age of 9-12 months and should be retested at least once a year (AIII). HIV-infected
children living in households with TST-positive persons should be evaluated for tuber-
culosis (AIII); children exposed to a person who has active tuberculosis should be
administered preventive therapy after active tuberculosis has been excluded, regard-
less of their TST results (All).
Pregnant Women
13. Chemoprophylaxis for tuberculosis is recommended during pregnancy for HIV-
infected patients who have either a positive TST or a history of exposure to active
tuberculosis, after active tuberculosis has been excluded (AIII). A chest radiograph
should be obtained before treatment and appropriate abdominal/pelvic lead apron
shields should be used to minimize radiation exposure to the embryo/fetus. When an
HIV-infected person has not been exposed to drug-resistant TB, isoniazid daily or
twice weekly is the prophylactic regimen of choice. Because of concerns regarding
possible teratogenicity associated with drug exposures during the first trimester,
providers may choose to initiate prophylaxis after the first trimester. Preventive ther-
apy with isoniazid should be accompanied by pyridoxine to reduce the risk for
neurotoxicity. Experience with rifampin or rifabutin during pregnancy is more limited,
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but anecdotal experience with rifampin has not been associated with adverse preg-
nancy outcomes. Pyrazinamide should generally be avoided, particularly in the first
trimester because of lack of information concerning fetal effects.
Disseminated Infection with Mycobacterium avium Complex
Prevention ofExposure
1. Organisms of the M. avium complex (MAC) are common in environmental
sources such as food and water. Current information does not support specific recom-
mendations regarding avoidance of exposure.
Prevention of Disease
Initiation of Primary Prophylaxis
2. Adults and adolescents who have HIV infection should receive chemoprophy-
laxis against disseminated MAC disease if they have a CD4+ T-lymphocyte count of
<50 cells/L (AI) (4). Clarithromycin (39,40) or azithromycin (41) are the preferred
prophylactic agents (AI). The combination of clarithromycin and rifabutin is no more
effective than clarithromycin alone for chemoprophylaxis and is associated with a
higher rate of adverse effects than either drug alone; this combination should not be
used (El) (39). The combination of azithromycin with rifabutin is more effective than
azithromycin alone; however, the additional cost, increased occurrence of adverse
effects, potential for drug interactions, and absence of a difference in survival when
compared with azithromycin alone do not warrant a routine recommendation for this
regimen (CI) (41 ). In addition to their preventive activity for MAC disease, clarithromy-
cin and azithromycin each confer protection against respiratory bacterial infections
(BII). If clarithromycin or azithromycin cannot be tolerated, rifabutin is an alternative
prophylactic agent for MAC disease (BI) (39,41,42). Tolerance, cost, and drug interac-
tions are among the issues that should be considered in decisions regarding the
choice of prophylactic agents for MAC disease. Particular attention to interactions
with antiretroviral protease inhibitors and nonnucleoside reverse transcriptase inhibi-
tors is warranted (see Special Considerations/Drug Interactions, page 15). Before
prophylaxis is initiated, disseminated MAC disease should be ruled out by clinical
assessment, which might include obtaining a blood culture for MAC if warranted.
Because treatment with rifabutin could result in the development of resistance to
rifampin in persons who have active tuberculosis, active tuberculosis should also be
excluded before rifabutin is used for prophylaxis.
3. Although the detection of MAC organisms in the respiratory or gastrointestinal
tract might predict the development of disseminated MAC infection, no data are avail-
able on the efficacy of prophylaxis with clarithromycin, azithromycin, rifabutin, or
other drugs in patients with MAC organisms at these sites and a negative blood cul-
ture. Therefore, routine screening of respiratory or gastrointestinal specimens for
MAC cannot be recommended (Dill).
Discontinuation of Primary Prophylaxis
4. Information from observational studies suggested a low rate of disseminated
infection with MAC among persons who responded to HAART with an increase in
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CD4+ T-lymphocyte count from <50 cells/#L to >100 cells/#L (32,43). Although the
optimal criteria for discontinuing MAC prophylaxis remain to be defined, a reasonable
option would be to consider discontinuing prophylaxis in patients with a CD4+
T-lymphocyte count of >100 cells/#L for a sustained period (e.g., >3-6 months) and
sustained suppression of HIV plasma RNA for a similar period (CII).
Restarting Primary Prophylaxis
5. No data are available on which to base recommendations for reinstituting pro-
phylaxis. Pending the availability of such data, a reasonable approach would be to use
the criteria for initiating prophylaxis described on page 14 (CIII).
Prevention ofRecurrence
6. Patients who have been treated for disseminated MAC disease should continue
to receive full therapeutic doses of antimycobacterial agents for life (i.e., secondary
prophylaxis or chronic maintenance therapy) (All) (42). Unless good clinical or labora-
tory evidence of macrolide resistance exists, the use of a macrolide (clarithromycin or,
alternatively, azithromycin)is recommended in combination with ethambutol (All)
with or without rifabutin (CI) (44,45). Treatment of MAC disease with clarithromycin in
a dose of 1,000 mg twice a day is associated with a higher mortality rate than has been
observed with clarithromycin administered at 500 mg twice a day; thus, the higher
dose should not be used (El) (46,4.7). Clofazimine has been associated with an adverse
clinical outcome in the treatment of MAC disease and should not be used (DII) (47,48).
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)
7. Although patients receiving chronic maintenance therapy for MAC might be at
low risk for recurrence of MAC when their CD4+ T-lymphocyte counts increase to
>100 cells/#L following 6-12 months of HAART, the numbers of patients who have
been evaluated are insufficient to warrant a recommendation to discontinue mainte-
nance therapy in such patients.
Special Considerations
Drug Interactions
8. Rifabutin should not be administered with certain protease inhibitors or
nonnucleoside reverse transcriptase inhibitors (see Special Considerations/Drug
Interactions in Tuberculosis section, page 13). Although protease inhibitors might also
increase clarithromycin levels, no recommendation to adjust the dose of either
clarithromycin or protease inhibitors can be made on the basis of existing data.
Children
9. HIV-infected children aged <13 years who have advanced immunosuppression
also can develop disseminated MAC infections, and prophylaxis should be offered
to high-risk children according to the following CD4+ T-lymphocyte thresholds: chil-
dren aged >_6 years, <50 cells/#L; children aged 2-6 years, <75 cells/#L; children aged
1-2 years, <500 cells/#L; and children aged <12 months, <750 cells/#L (All). For the
same reasons that clarithromycin and azithromycin are the preferred prophylactic
agents for adults, they should also be considered for children (All); oral suspensions
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of both agents are commercially available in the United States. No liquid formulation
of rifabutin suitable for pediatric use is commercially available in the United States.
The safety of discontinuing MAC prophylaxis in children whose CD4+ T-lymphocyte
counts have increased in response to HAART has not been studied.
Pregnant Women
10. Chemoprophylaxis for MAC disease should be administered to pregnant
women as is done for other adults and adolescents (AIII). However, because of general
concerns about administering drugs during the first trimester of pregnancy, some
providers may choose to withhold prophylaxis during the first trimester. Animal stud-
ies and anecdotal evidence of safety in humans suggest that of the available agents,
azithromycin is the drug of choice (Bill) (49). Experience with rifabutin is limited.
Clarithromycin has been demonstrated to be a teratogen in animals and should be
used with caution during pregnancy (50). For secondary prophylaxis (chronic mainte-
nance therapy), azithromycin plus ethambutol are the preferred drugs (Bill).
Bacterial Respiratory Infections
Prevention ofExposure
1. Because Streptococcus pneumoniae and Haemophilus influenzae are common
in the community, no effective way exists to reduce exposure to these bacteria.
Prevention of Disease
2. As soon as feasible after HIV infection is diagnosed, adults and adolescents who
have a CD4+ T-lymphocyte count of z200 cells/#L should be administered a single
dose of 23-valent polysaccharide pneumococcal vaccine if they have not had this vac-
cine during the previous 5 years (BII) (51,52). For persons who have a CD4+
T-lymphocyte count of <200 cells/#L, vaccination can be offered, although the humoral
response and clinical efficacy are likely to be diminished (CIII). The recommendation
to vaccinate is increasingly pertinent because of the increasing incidence of invasive
infections with drug-resistant (including TMP-SMZ-, macrolide-, penicillin-, and beta-
lactam-resistant) strains of S. pneumoniae. Limited data suggest that administration
of certain bacterial vaccines might transiently increase HIV replication and plasma
HIV-1 RNA levels in a minority of HIV-infected persons. However, there is no evidence
that adverse clinical outcomes are associated with this transient increase. Most
experts believe that the benefit of pneumococcal vaccination outweighs the potential
risk.
3. The duration of the protective effect of primary pneumococcal vaccination is
unknown. Periodic revaccination may be considered; an interval of 5 years has been
recommended for persons not infected with HIV and also might be appropriate for
persons infected with HIV (53). In addition, revaccination one time should also be
considered if the initial vaccination was given when the CD4+ T-lymphocyte count was
<200 cells/#L and if the CD4+ T-lymphocyte count has increased to >200 cells/#L as a
result of HAART (CIII).
4. The incidence of H. influenzae type B infection in adults is low. Therefore, H. in-
fluenzae type B vaccine is not generally recommended for adult use (Dill).
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5. TMP-SMZ, when administered daily for PCP prophylaxis, reduces the frequency
of bacterial respiratory infections; this should be considered in the selection of an
agent for PCP prophylaxis (All). However, indiscriminate use of this drug (when not
indicated for PCP prophylaxis or other specific reasons) might promote the develop-
ment of TMP-SMZ-resistant organisms. Thus, TMP-SMZ should not be prescribed
solely to prevent bacterial respiratory infection (Dill). Similarly, clarithromycin admin-
istered daily and azithromycin administered weekly for MAC prophylaxis might be
effective in preventing bacterial respiratory infections; this should be considered in
the selection of an agent for prophylaxis against MAC disease (BII). However, these
drugs should not be prescribed solely for preventing bacterial respiratory infection
(Dill).
6. An absolute neutrophil count that is depressed because of HIV disease or drug
therapy is associated with an increased risk for bacterial infections, including pneumo-
nia. To reduce the risk for such bacterial infections, providers may consider taking
steps to reverse neutropenia, either by stopping myelosuppressive drugs (CII) or by
administering granulocyte-colony-stimulating factor (G-CSF) (CII).
Prevention ofRecurrence
7. Some clinicians may administer antibiotic chemoprophylaxis to HIV-infected
patients who have very frequent recurrences of serious bacterial respiratory infections
(CIII). TMP-SMZ, administered for PCP prophylaxis, and clarithromycin or azith.romy-
cin, administered for MAC prophylaxis, are appropriate for drug-sensitive organisms.
However, providers should be cautious about using antibiotics solely for preventing
the recurrence of serious bacterial respiratory infections because of the potential
development of drug-resistant microorganisms and drug toxicity.
Special Considerations
Children
8. Children who have HIV infection should be administered H. influenzae type b
vaccine in accordance with the guidelines of the Advisory Committee on Immuniza-
tion Practices (54) and the American Academy of Pediatrics (55) (All). Children aged
>2 years also should be administered 23-valent polysaccharide pneumococcal vaccine
(BII). Revaccination with pneumococcal vaccine generally should be offered after
3-5 years to children aged <10 years and after 5 years to children aged 10 years (Bill).
9. To prevent serious bacterial infections in HIV-infected children who have
hypogammaglobulinemia (IgG <400 mg/dL), clinicians should use intravenous immu-
noglobulin (IVIG) (AI). Respiratory syncytial virus (RSV) IVIG (750 mg/kg), not
monoclonal RSV antibody, may be substituted for IVIG during the RSV season to pro-
vide broad anti-infective protection, if RSV IVIG is available.
10. To prevent recurrence of serious bacterial respiratory infections, antibiotic
chemoprophylaxis may be considered (BI). However, providers should be cautious
about using antibiotics solely for this purpose because of the potential development
of drug-resistant microorganisms and drug toxicity. The administration of IVIG should
also be considered for HIV-infected children who have recurrent serious bacterial
infections (BI), although such treatment might not provide additional benefit to chil-
dren who are being administered daily TMP-SMZ. However, IVIG may be considered
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for children who have recurrent serious bacterial infections despite receiving TMP-
SMZ or other antimicrobials (CIII).
Pregnant Women
11. Pneumococcal vaccination is recommended during pregnancy for HIV-infected
patients who have not been vaccinated during the previous 5 years (Bill). Among non-
pregnant adults, vaccination has been associated with a transient burst of HIV
replication. Whether the transient viremia can increase the risk for perinatal HIV trans-
mission is unknown. Because of this concern, when feasible, vaccination may be
deferred until after antiretroviral therapy has been initiated to prevent perinatal HIV
transmission (CIII).
Bacterial Enteric Infections
Prevention ofExposure
Food
1. Health-care providers should advise HIV-infected persons not to eat raw or
undercooked eggs (including foods that might contain raw eggs [e.g., some prepara-
tions of hollandaise sauce, Caesar and other salad dressings, and mayonnaise]); raw
or undercooked poultry, meat, or seafood; or unpasteurized dairy products. Poultry
and meat should be well cooked and should not be pink in the middle (internal tem-
perature >165 F [73.8 C]). Produce should be washed thoroughly before being eaten
(Bill).
2. Health-care providers should advise HIV-infected persons to avoid cross-
contamination of foods. Uncooked meats should not come into contact with other
foods. Hands, cutting boards, counters, knives, and other utensils should be washed
thoroughly after contact with uncooked foods (Bill).
3. Health-care providers should advise HIV-infected persons that, although the inci-
dence of listeriosis is low, it is a serious disease that occurs with unusually high
frequency among HIV-infected persons who are severely immunosuppressed. Such
persons may choose to avoid soft cheeses because some studies have shown an
association between these foods and listeriosis. These studies also have documented
an association between ready-to-eat foods (e.g., hot dogs and cold cuts from delica-
tessen counters) and listeriosis. An immunosuppressed, HIV-infected person who
wishes to reduce the risk for foodborne disease as much as possible may choose to
reheat such foods until they are steaming hot before eating them (CIII).
Pets
4. When obtaining a new pet, HIV-infected persons should avoid animals aged
<6 months, especially those that have diarrhea (Bill).
5. HIV-infected persons should avoid contact with animals that have diarrhea (Bill).
HIV-infected pet owners should seek veterinary care for animals with diarrheal illness,
and a fecal sample from such animals should be examined for Cryptosporidium,
Salmonella, and Campylobacter.
6. HIV-infected persons should wash their hands after handling pets (especially
before eating) and should avoid contact with pets’ feces (Bill).
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7. HIV-infected persons should avoid contact with reptiles (e.g., snakes, lizards,
iguanas, and turtles) because of the risk for salmonellosis (Bill).
Travel
8. The risk for foodborne and waterborne infections among immunosuppressed,
HIV-infected persons is magnified during travel to developing countries. Persons who
travel to such countries should avoid foods and beverages that might be contami-
nated, particularly raw fruits and vegetables, raw or undercooked seafood or meat,
tap water, ice made with tap water, unpasteurized milk and dairy products, and items
sold by street vendors (All). Foods and beverages that are generally safe include
steaming-hot foods, fruits that are peeled by the traveler, bottled (especially carbon-
ated) beverages, hot coffee and tea, beer, wine, and water brought to a rolling boil for
1 minute (All). Treatment of water with iodine or chlorine might not be as effective as
boiling but can be used when boiling is not practical (Bill).
Prevention of Disease
9. Prophylactic antimicrobial agents are not generally recommended for travelers
(Dill). The effectiveness of these agents depends on local antimicrobial-resistance pat-
terns of gastrointestinal pathogens, which are seldom known. Moreover, these agents
can elicit adverse reactions and can promote the emergence of resistant organisms.
However, for HIV-infected travelers, antimicrobial prophylaxis may be considered,
depending on the level of immunosuppression and the region and duration of travel
(CIII). The use of fluoroquinolones such as ciprofloxacin (500 mg per day) can be con-
sidered when prophylaxis is deemed necessary (Bill). As an alternative (e.g., for
children, pregnant women, and persons already taking TMP-SMZ for PCP prophy-
laxis), TMP-SMZ might offer some protection against traveler’s diarrhea (Bill). The risk
of toxicity should be considered before treatment with TMP-SMZ is initiated solely
because of travel.
10. Antimicrobial agents such as fluoroquinolones should be given to patients
before their departure, to be taken empirically (e.g., 500 mg of ciprofloxacin twice a
day for 3-7 days) should traveler’s diarrhea develop (Bill). Fluoroquinolones should be
avoided for children aged <18 years and pregnant women, and alternative antibiotics
should be considered (Bill). Travelers should consult a physician if their diarrhea is
severe and does not respond to empirical therapy, if their stools contain blood, if fever
is accompanied by shaking chills, or if dehydration develops. Antiperistaltic agents
(e.g., diphenoxylate and Ioperamide) can be used to treat mild diarrhea. However, the
use of these drugs should be discontinued if symptoms persist beyond 48 hours.
Moreover, these agents should not be administered to patients who have a high fever
or who have blood in the stool (All).
11. Some experts recommend that HIV-infected persons who have Salmonella gas-
troenteritis be administered antimicrobial therapy to prevent extraintestinal spread of
the pathogen. However, no controlled study has demonstrated a beneficial effect of
such treatment, and some studies of immunocompetent persons have suggested that
antimicrobial therapy can lengthen the shedding period. The fluoroquinolones
primarily ciprofloxacin (750 mg twice a day for 14 days)-- can be used when antimi-
crobial therapy is chosen (CIII).
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Prevention ofRecurrence
12. HIV-infected persons who have Salmonella septicemia require long-term
therapy (i.e., secondary prophylaxis or chronic maintenance therapy) to prevent
recurrence. Fluoroquinolones, primarily ciprofloxacin, are usually the drugs of choice
for susceptible organisms (BII).
13. Householdcontacts of HIV-infected persons who have salmonellosis or shigel-
Iosis should be evaluated for persistent asymptomatic carriage of Salmonella or
Shigeila so that strict hygienic measures and/or antimicrobial therapy can be insti-
tuted and recurrent transmission to the HIV-infected person can be prevented (CIlI).
Special Considerations
Children
14. Like HIV-infected adults, HIV-infected children should wash their hands after
handling pets (especially before eating) and should avoid contact with pets’ feces.
Hand washing should be supervised (Bill).
15. HIV-exposed infants aged <3 months and all HIV-infected children who have
severe immunosuppression should be administered treatment for Salmonella gastro-
enteritis to prevent extraintestinal spread of the pathogen (CIII). Choices of antibiotics
include TMP-SMZ, ampicillin, cefotaxime, ceftriaxone, or chloramphenicol; fluoroqui-
nolones should be used with caution and only if no alternatives exist.
16. HIV-infected children who have Salmonella septicemia should be offered long-
term therapy to prevent recurrence (CIII). TMP-SMZ is the drug of choice; ampicillin or
chloramphenicol can be used if the organism is susceptible. Fluoroquinolones should
be used with caution and only if no alternative exists.
17. Antiperistaltic drugs are not recommended for children (Dill).
Pregnant Women
18. Because both pregnancy and HIV infection confer a risk for listeriosis, pregnant
HIV-infected women should heed recommendations regarding listeriosis (BII).
19. Because extraintestinal spread of Salmonella during pregnancy might lead to
infection of the placenta and amniotic fluid and result in pregnancy loss similar to that
seen with Listeria monocytogenes, pregnant women with Salmonella gastroenteritis
should receive treatment (Bill). Choices for treatment include ampicillin, cefotaxime,
ceftriaxone, or TMP-SMZ. Fluoroquinolones should be avoided.
20. Fluoroquinolones should not be used during pregnancy. TMP-SMZ might offer
some protection against traveler’s diarrhea.
Infection with Bartonella (Formerly Rochalimaea )
Prevention ofExposure
1. HIV-infected persons, particularly those who are severely immunosuppressed,
are at unusually high risk for developing relatively severe disease due to infection with
Bartonella, which can be transmitted from cats. These persons should consider the
potential risks of cat ownership (CIII). Persons who acquire a cat should adopt or pur-
chase an animal aged >1 year that is in good health (BII).
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2. Although declawing is not generally advised, HIV-infected persons should
avoid rough play with cats and situations in which scratches are likely (BII). Any cat-
associated wound should be washed promptly (CIII). Cats should not be allowed to lick
open wounds or cuts of HIV-infected persons (Bill).
3. Care of cats should include flea control (CIII).
4. No evidence indicates any benefits to cats or their owners from routine culture or
serologic testing of the pet for Bartonella infection (DII).
Prevention of Disease
5. No data support chemoprophylaxis for Bartonella-associated disease (CIII).
Prevention ofRecurrence
6. Relapse or reinfection with Bartonella has sometimes followed a course of
primary treatment. Although no firm recommendation can be made regarding
prophylaxis in this situation, long-term suppression of infection with erythromycin or
doxycycline should be considered (CIII).
Special Considerations
Children
7. The risks of cat ownership for HIV-infected children who are severely immuno-
compromised should be discussed with parents and caretakers (Clll).
Pregnant Women
8. If long-term suppression of Bartonella infection is required, erythromycin should
be used. Tetracyclines should not be used during pregnancy.
Candidiasis
Prevention of Exposure
1. Candida organisms are common on mucosal surfaces and skin. No measures are
available to reduce exposure to these fungi.
Prevention of Disease
2. Data from prospective controlled trials indicate that fluconazole can reduce the
risk for mucosal (oropharyngeal, esophageal, and vaginal) candidiasis and cryptococ-
cosis as well in patients with advanced HIV disease (56-58). However, routine primary
prophylaxis is not recommended because of the effectiveness of therapy for acute
disease, the low mortality associated with mucosal candidiasis, the potential for resis-
tant Candida organisms to develop, the possibility of drug interactions, and the cost of
prophylaxis (Dill).
Prevention of Recurrence
3. Many experts do not recommend chronic prophylaxis of recurrent
oropharyngeal or vulvovaginal candidiasis for the same reasons that they do not
recommend primary prophylaxis. However, if recurrences are frequent or severe,
INt,’ECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 251999 USPHS/IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS
providers may consider administering an oral azole (fluconazole [CI] [56] or itracona-
zole solution [CI]). Other factors that influence choices about such therapy include the
impact of the recurrences on the patient’s well-being and quality of life, the need for
prophylaxis for other fungal infections, cost, toxicities, drug interactions, and the
potential to induce drug resistance among Candida and other fungi. Prolonged use of
systemically absorbed azoles, particularly in patients with low CD4+ T-lymphocyte
counts (i.e., <100 cells/tL), increases the risk for the development of azole resistance.
4. Adults or adolescents who have a history of documented esophageal candidi-
asis, particularly multiple episodes, should be considered candidates for chronic
suppressive therapy. Fluconazole at a dose of 100-200 mg daily is appropriate (BI).
However, the potential development of azole resistance should be taken into account
when long-term azoles are considered.
Special Considerations
Children
5. Primary prophylaxis of candidiasis in HIV-infected infants is not indicated (Dill).
6. Suppressive therapy with systemic azoles should be considered for infants who
have severe recurrent mucocutaneous candidiasis (CIII) and particularly for those who
have esophageal candidiasis (Bill).
Pregnant Women
7. Experience is limited with the use of systemic antifungal drugs during human
pregnancy. Four cases of infants born with craniofacial and skeletal abnormalities
following prolonged in utero exposure to fluconazole have been reported (59,50). In
addition, itraconazole is embryotoxic and teratogenic in animal systems (61). These
same potential risks of teratogenicity are presumed to apply to other systemically
absorbed azole antifungals, such as ketoconazole. Therefore, chemoprophylaxis
against oropharyngeal, esophageal, or vaginal candidiasis using systemically
absorbed azoles should not be initiated during pregnancy (Dill), and azoles should be
discontinued for HIV-infected women who become pregnant (Dill). Effective birth con-
trol measures should be recommended to all HIV-infected women on azole therapy for
candidiasis (AIII).
Cryptococcosis
Prevention ofExposure
1. HIV-infected persons cannot completely avoid exposure to Cryptococcus neofor-
mans. No evidence exists that exposure to pigeon droppings is associated with an
increased risk for acquiring cryptococcosis.
Prevention ofDisease
2. Routine testing of asymptomatic persons for serum cryptococcal antigen is not
recommended because of the low probability that the results will affect clinical deci-
sions (Dill).
3. Prospective controlled trials indicate that fluconazole and itraconazole can
reduce the frequency of cryptococcal disease among patients who have advanced HIV
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disease. However, most experts recommend that antifungal prophylaxis not be used
routinely to prevent cryptococcosis because of the relative infrequency of cryptococ-
cal disease, the lack of survival benefits associated with prophylaxis, the possibility of
drug interactions, the potential development of antifungal drug resistance, and cost.
The need for prophylaxis or suppressive therapy for other fungal infections (e.g., can-
didiasis, histoplasmosis, or coccidioidomycosis) should be considered in making
decisions about prophylaxis for cryptococcosis. If used, fluconazole at doses of 100-
200 mg daily is reasonable for patients whose CD4+ T-lymphocyte counts are
<50 cells/#L (CI) (56-58).
Prevention of Recurrence
4. Patients who complete initial therapy for cryptococcosis should be administered
lifelong suppressive treatment (i.e., secondary prophylaxis or chronic maintenance
therapy). Fluconazole is superior to itraconazole in preventing relapse of cryptococcal
disease and is the preferred drug (AI).
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)
5. Although patients receiving secondary prophylaxis (chronic maintenance ther-
apy) might be at low risk for recurrence of systemic mycosis when their CD4+
T-lymphocyte counts increase to >100 cells/#L on HAART, the numbers of patients who
have been evaluated are insufficient to warrant a recommendation to discontinue
prophylaxis.
Special Considerations
Children
6. No data exist on which to base specific recommendations for children, but life-
long suppressive therapy with fluconazole after an episode of cryptococcosis is
appropriate (All).
Pregnant Women
7. Prophylaxis with fluconazole or itraconazole should not be initiated during preg-
nancy because of the low incidence of cryptococcal disease, the lack of a rec-
ommendation for primary prophylaxis against cryptococcosis in nonpregnant adults,
and potential teratogenic effects of these drugs during pregnancy (Dill) (59-61). For
patients who conceive while being administered primary prophylaxis and who elect to
continue their pregnancy, prophylaxis should be discontinued. The occurrence of
craniofacial and skeletal abnormalities in infants following prolonged in utero expo-
sure to fluconazole should be considered when assessing the therapeutic options for
HIV-infected women who become pregnant and are receiving secondary prophylaxis
(chronic maintenance therapy) for cryptococcosis (59,60). For such patients, therapy
with amphotericin B may be preferred, especially during the first trimester. Effective
birth control measures should be recommended to all HIV-infected women on azole
therapy for cryptococcosis (AIII).
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Histoplasmosis
Prevention ofExposure
1. Although HIV-infected persons living in or visiting histoplasmosis-endemic areas
cannot completely avoid exposure to Histoplasma capsulatum, those whose CD4+
T-lymphocyte counts are <200 cells/lL should avoid activities known to be associated
with increased risk (e.g., creating dust when working with surface soil; cleaning
chicken coops that are heavily contaminated with droppings; disturbing soil beneath
bird-roosting sites; cleaning, remodeling, or demolishing old buildings; and exploring
caves) (CIII).
Prevention of Disease
2. Routine skin testing with histoplasmin and serologic testing for antibody or anti-
gen in histoplasmosis-endemic areas are not predictive of disease and should not be
performed (DII).
3. Data from a prospective randomized controlled trial indicate that itraconazole
can reduce the frequency of histoplasmosis among patients who have advanced HIV
infection and who live in H. capsulatum-endemic areas (62). However, no survival
benefit was observed among persons receiving itraconazole. Prophylaxis with itra-
conazole may be considered in patients with CD4+ T-lymphocyte counts <100 cells/L
who are at especially high risk because of occupational exposure or who live in a
community with a hyperendemic rate of histoplasmosis (>10 cases per 100 patient-
years) (CI).
Prevention ofRecurrence
4. Patients who complete initial therapy for histoplasmosis should be administered
lifelong suppressive treatment (i.e., secondary prophylaxis or chronic maintenance
therapy) with itraconazole (200 mg twice a day) (AI) (63).
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)
-5. Although patients receiving secondary prophylaxis (chronic maintenance ther-
apy) might be at low risk for recurrence of systemic mycosis when their CD4+
T-lymphocyte counts increase to >100 cells/L on HAART, the numbers of patients who
have been evaluated are insufficient to warrant a recommendation to discontinue
prophylaxis.
Special Considerations
Children
6. Because .primary histoplasmosis can lead to disseminated infection in children, a
reasonable option is to administer lifelong suppressive therapy after an acute episode
of the disease (AIII).
Pregnant Women
7. Because of the embryotoxicity and teratogenicity of itraconazole in animal sys-
tems, primary prophylaxis against histoplasmosis should not be offered during
pregnancy (Dill). These data as well as the observation of craniofacial and skeletal
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abnormalities in infants following prolonged in utero exposure to fluconazole should
be considered when assessing the need for chronic maintenance therapy in HIV-
infected pregnant women with histoplasmosis. For such patients, therapy with
amphotericin B may be preferred, especially during the first trimester. Effective birth
control measures should be recommended to all HIV-infected women on azole ther-
apy for histoplasmosis (AIII).
Coccidioidomycosis
Prevention ofExposure
1. Although HIV-infected persons living in or visiting areas in which coccidioidomy-
cosis is endemic cannot completely avoid exposure to Coccidioides immitis, they
should, when possible, avoid activities associated with increased risk (e.g., those
involving extensive exposure to disturbed native soil, for example, at building excava-
tion sites or during dust storms) (CIII).
Prevention of Disease
2. Routine skin testing with coccidioidin (spherulin) in coccidioidomycosis-endemic
areas is not predictive of disease and should not be performed (DII). Within the
endemic area, a positive serologic test might indicate an increased risk for active
infection; however, routine testing does not appear to be useful and should not be
performed (Dill).
3. Primary prophylaxis for HIV-infected persons who live in coccidioidomycosis-
endemic areas is not routinely recommended.
Prevention of Recurrence
4. Patients who complete initial therapy for coccidioidomycosis should be adminis-
tered lifelong suppressive therapy (i.e., secondary prophylaxis or chronic main-
tenance therapy) (All) using either 400 mg of fluconazole by mouth each day or
200 mg of itraconazole twice a day (64). Patients with meningeal disease require con-
sultation with an expert.
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)
5. Although patients receiving secondary prophylaxis (chronic maintenance ther-
apy) might be at low risk for recurrence of systemic mycosis when their CD4+
T-lymphocyte counts increase to >100 cells/L on HAART, the numbers of patients who
have been evaluated are insufficient to warrant a recommendation to discontinue
prophylaxis.
Special Considerations
Children
6. Although no specific data are available regarding coccidioidomycosis in HIV-
infected children, a reasonable option is to administer lifelong suppressive therapy
after an acute episode of the disease (AIII).
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Pregnant Women
7. The potential teratogenicity of fluconazole and itraconazole should be consid-
ered when assessing the therapeutic options for HIV-infected women who become
pregnant while receiving chronic maintenance therapy for coccidiodomycosis. For
such patients, therapy with amphotericin B may be preferred, especially during the
first trimester. Effective birth control measures should be recommended for all HIV-
infected women on azole therapy for coccidioidomycosis (AIII).
Cytomegalovirus Disease
Prevention ofExposure
1. HIV-infected persons who belong to risk groups with relatively low rates of sero-
positivity for cytomegalovirus (CMV) and who therefore cannot be presumed to be
seropositive should be tested for antibody to CMV (Bill). These groups include
patients who have not had male homosexual contact or used injection drugs.
2. HIV-infected adolescents and adults should be advised that CMV is shed in
semen, cervical secretions, and saliva and that latex condoms must always be used
during sexual contact to reduce the risk for exposure to CMV and to other sexually
transmitted pathogens (All).
3. HIV-infected adults and adolescents who are child-care providers or parents of
children in child-care facilities should be informed that they are at increased risk for
acquiring CMV infection (BI). Similarly, parents and other caretakers of HIV-infected
children should be advised of the increased risk to children at these centers (Bill). The
risk for acquiring CMV infection can be diminished by good hygienic practices such as
hand washing (All).
4. HIV-exposed infants and HIV-infected children, adolescents, and adults who are
seronegative for CMV and require blood transfusion should be administered only
CMV antibody-negative or leukocyte-reduced cellular blood products in nonemer-
gency situations (Bill).
Prevention of Disease
5. Prophylaxis with oral ganciclovir may be considered for HIV-infected adults and
adolescents who are CMV seropositive and who have a CD4+ T-lymphocyte count of
<50 cells/#L (CI) (65,66). Ganciclovir-induced neutropenia, anemia, conflicting reports
of efficacy, lack of proven survival benefit, the risk for developing ganciclovir-resistant
CMV, and cost are among the issues that should be considered when deciding
whether to institute prophylaxis in individual patients. Acyclovir is not effective in
preventing CMV disease, and valacyclovir is not recommended because of an unex-
plained trend toward increased deaths among persons with AIDS who were
administered valacyclovir for CMV prophylaxis (67). Therefore, neither acyclovir nor
valacyclovir should be used for this purpose (El). The most important method for pre-
venting severe CMV disease is recognition of the early manifestations of the disease.
Early recognition of CMV retinitis is most likely when the patient has been educated on
this topic. Patients should be made aware of the significance of increased floaters in
the eye and should be advised to assess their visual acuity regularly by using simple
techniques such as reading newsprint (Bill). Regular funduscopic examinations
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performed by an ophthalmologist are recommended by some experts for patients
with low (e.g., <50 cells/[L) CD4+ T-lymphocyte counts (CIII).
Prevention of Recurrence
6. CMV disease is not cured with courses of the currently available antiviral agents
(e.g., ganciclovir, foscarnet, or cidofovir). Following induction therapy, secondary pro-
phylaxis (chronic maintenance therapy)is recommended for life (AI). Regimens that
are effective for chronic suppression include parenteral or oral ganciclovir, parenteral
foscarnet, combined parenteral ganciclovir and foscarnet, parenteral cidofovir, and
(for retinitis only) ganciclovir administration via intraocular implant plus oral ganci-
clovir (AI) (68-72). The intraocular implant alone does not provide protection to the
contralateral eye or to other organ systems. The choice of a chronic maintenance regi-
men for patients treated for CMV disease should be made in consultation with an
expert. For patients with retinitis, this decision should be made in consultation with an
ophthalmologist and should take into consideration the anatomic location of the reti-
nal lesion, vision in the contralateral eye, the immunologic and virologic status of the
patient, and the patient’s response to HAART (Bill).
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)
7. Several studies have found that maintenance therapy can be discontinued in
patients with CMV retinitis whose CD4+ T-lymphocyte counts have increased to >100-
150 cells/#L and whose HIV plasma RNA levels have been suppressed in response to
HAART (73-75). These patients largely have remained disease-free for >30-90 weeks,
whereas in the pre-HAART era, retinitis typically recurred in 6-8 weeks. Discontinu-
ation of prophylaxis may be considered in patients with a sustained (e.g., >3-6 month)
increase in CD4+ T-lymphocyte count to >100-150 cells/#L on HAART (CIlI). Such deci-
sions should be made in consultation with an ophthalmologist and should take into
account such factors as magnitude and duration of CD4+ T-lymphocyte increase, mag-
nitude and duration of viral load suppression, anatomic location of the retinal lesion,
vision in the contralateral eye, and the feasibility of regular ophthalmic monitoring
(CII) (73-75).
Restarting Secondary Prophylaxis
8. No data exist to guide recommendations for reinstituting secondary prophylaxis.
Pending the availability of such data, a reasonable approach would be to restart pro-
phylaxis when the CD4+ T-lymphocyte count has decreased to <50-100 cells/#L (CIII).
Special Considerations
Children
9. Some experts recommend obtaining a CMV urine culture on all HIV-infected (or
exposed) infants at birth or at an early postnatal visit to identify those infants with
congenital CMV infection (CIII). In addition, beginning at 1 year of age, CMV antibody
testing on an annual basis may be considered for CMV-seronegative (and culture-
negative) HIV-infected infants and children who are severely immunosuppressed
(Table 9) (CIII). Annual testing will allow identification of children who have acquired
CMV infection and might benefit from screening for retinitis.
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10. HIV-infected children who are CMV-infected and severely immunosuppressed
might benefit from a dilated retinal examination performed by an ophthalmologist
every 4-6 months (CIII). In addition, older children should be counseled to be aware of
floaters in the eye, similar to the recommendation for adults (Bill).
11. Oral ganciclovir results in reduced CMV shedding in CMV-infected children
and may be considered for primary prophylaxis against CMV disease in CMV-infected
children who are severely immunosuppressed (e.g., CD4+ T-lymphocyte count
<50 cells/tL) (CII).
12. For children with CMV disease, no data are available to guide decisions con-
cerning discontinuation of secondary prophylaxis (chronic maintenance therapy)
when the CD4+ T-lymphocyte count has increased in response to HAART.
Pregnant Women
13. Because of the lack of a recommendation for routine use of ganciclovir among
nonpregnant adults and the lack of experience with this drug during pregnancy, gan-
ciclovir is not recommended for primary prophylaxis against CMV disease during
pregnancy (Dill). Ganciclovir should be discontinued for patients who conceive while
being administered primary prophylaxis. Because of the risks to maternal health, pro-
phylaxis against recurrent CMV disease is indicated during pregnancy (AIII). The
choice of agents to be used in pregnancy should be individualized after consultation
with experts.
Herpes Simplex Virus Disease
Prevention of Exposure
1. HIV-infected persons should use latex condoms during every act of sexual inter-
course to reduce the risk for exposure to herpes simplex virus (HSV) and to other
sexually transmitted pathogens (All). They should specifically avoid sexual contact
when herpetic lesions (genital or orolabial) are evident (All).
Prevention of Disease
2. Prophylaxis of initial episodes of HSV disease is not recommended (Dill).
Prevention of Recurrence
3. Because acute episodes of HSV infection can be treated successfully, chronic
therapy with acyclovir is not required after lesions resolve. However, persons who
have frequent or severe recurrences can be administered daily suppressive therapy
with oral acyclovir or famciclovir (AI) (76,77). Valacyclovir also is an option (CIII). Intra-
venous foscarnet or cidofovir can be used to treat infection due to acyclovir-resistant
isolates of HSV, which are routinely resistant to ganciclovir as well (All).
Special Considerations
Children
4. The recommendations for preventing initial disease and recurrence among
adults and adolescents aDlv to children as well.
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Pregnant Women
5. Oral acyclovir prophylaxis during late pregnancy is a controversial strategy
recommended by some experts to prevent neonatal herpes transmission. However,
such prophylaxis is not routinely recommended. For patients who have frequent,
severe recurrences of genital HSV disease, acyclovir prophylaxis might be indicated
(Bill). No pattern of adverse pregnancy outcomes has been reported after acyclovir
exposures (78).
Varicella-Zoster Virus Infection
Prevention ofExposure
1. HIV-infected children and adults who are susceptible to varicella-zoster virus
(VZV) (i.e., those who have no history of chickenpox or shingles or are seronegative
for VZV) should avoid exposure to persons with chickenpox or shingles (All). House-
hold contacts (especially children) of susceptible HIV-infected persons should be
vaccinated against VZV if they have no history of chickenpox and are seronegative for
HIV, so that they will not transmit VZV to their susceptible HIV-infected contacts (Bill).
Prevention of Disease
2, Very little data regarding the safety and efficacy of varicella vaccine in HIV-
infected adults are available, and no recommendation for its use can be made for this
population. (See Special Considerations/Children, below, for information about the
use of varicella vaccine in children.)
3. For the prophylaxis of chickenpox, HIV-infected children and adults who are sus-
ceptible to VZV (i.e., those who have no history of chickenpox or shingles orwho have
no detectable antibody against VZV) should be administered varicella zoster immune
globulin (VZIG) as soon as possible but within 96 hours after close contact with a
patient who has chickenpox or shingles (AIII). Data are lacking on the effectiveness of
acyclovir for preventing chickenpox in susceptible HIV-infected children or adults.
4. No preventive measures are currently available for shingles.
Prevention of Recurrence
5. No drug has been proven to prevent the recurrence of shingles in HIV-infected
persons.
Special Considerations
Children
6. HIV-infected children who are asymptomatic and not immunosuppressed (i.e., in
immunologic category 1, Table 9) should receive live attenuated varicella vaccine at
12-15 months of age or later (BII). Varicella vaccine should not be administered to
other HIV-infected children because of the potential for disseminated viral infection
(EIII).
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Pregnant Women
7. VZIG is recommended for VZV-susceptible, HIV-infected pregnant women within
96 hours after exposure to VZV (AIII). If oral acyclovir is used, VZV serology should be
performed so that the drug can be discontinued if the patient is seropositive for VZV
(Bill).
Human Herpesvirus 8 Infection
Prevention of Exposure
1. The mechanism of transmitting human herpesvirus 8 (HHV-8), the herpesvirus
associated with Kaposi’s sarcoma (KS), is not known. Epidemiologic evidence sug-
gests that sexual transmission is likely among men who have sex with men and can
occur among heterosexuals as well. However, the virus has been detected more fre-
quently in saliva than in semen from HHV-8-seropositive HIV-infected persons.
Although the efficacy of condom use for preventing HHV-8 infection has not been
established, HIV-infected persons should use latex condoms during every act of sex-
ual intercourse to reduce the risk for exposure to sexually transmitted pathogens (All).
Prevention of Disease
2. Because clinical use of routine serologic testing to identify HHV-8 infection has
not been established, no recommendation for serologic testing can be made at this
time.
3. Lower rates of KS have been observed among AIDS patients treated with ganci-
clovir or foscarnet for CMV retinitis (68). HHV-8 replication in vitro is inhibited by
ganciclovir, foscarnet, and cidofovir. However, because the efficacy and clinical use of
these drugs in preventing KS have not been established, no recommendation can be
made concerning the use of these or other drugs to prevent KS in individuals coin-
fected with HIV and HHV-8.
4. Potent antiretroviral drug combinations that suppress HIV replication reduce the
frequency of KS in HIV-infected persons and should be considered for all persons who
qualify for such therapy (BII).
Prevention of Recurrence
5. Effective suppression of HIV replication with antiretroviral drugs in HIV-infected
patients with KS might prevent KS progression or the development of new lesions
and should be considered for all persons with KS (BII).
Special Considerations
Children
6. In parts of the world where HHV-8 is endemic, horizontal transmission might
occur among young children, possibly via saliva. However, no recommendations are
currently available for preventing HHV-8 transmission from child to child.
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Human Papillomavirus Infection
Prevention ofExposure
1. HIV-infected persons should use latex condoms during every act of sexual inter-
course to reduce the risk for exposure to sexually transmitted pathogens (All),
although little evidence exists to suggest that condoms reduce the risk for infection
with human papillomavirus (HPV).
Prevention of Disease
HPV-associated Genital Epithelial Cancers in HIV-infected Women
2. After a complete history of previous cervical disease has been obtained, HIV-
infected women should have a pelvic examination and a Pap smear. In accordance
with the recommendation of the Agency for Health Care Policy and Research, the Pap
smear should be obtained twice in the first year after diagnosis of HIV infection and, if
the results are normal, annually thereafter (All).
3. If the results of the Pap smear are abnormal, care should be provided according
to the Interim Guidelines for Management ofAbnormal Cervical Cytology published
by a National Cancer Institute Consensus Panel and briefly summarized in Recom-
mendations 4-8, which follow (79).
4. For patients whose Pap smears are interpreted as atypical squamous cells of
undetermined significance (ASCUS), several management options are available; the
choice depends in part on whether the interpretation of ASCUS is qualified by a state-
ment indicating that a neoplastic process is suspected. Follow-up by Pap tests without
colposcopy is acceptable, particularly when the diagnosis of ASCUS is not qualified
further or the cytopathologist suspects a reactive process. In such situations, Pap tests
should be repeated every 4-6 months for 2 years until three consecutive smears have
been negative. If a second report of ASCUS occurs in the 2-year follow-up period, the
patient should be considered for colposcopic evaluation (Bill).
5. Women who have a diagnosis of unqualified ASCUS associated with severe
inflammation should be evaluated for an infectious process. If specific infections are
identified, reevaluation should be performed after appropriate treatment, preferably
after 2-3 months (Bill).
6. If the diagnosis of ASCUS is qualified by a statement indicating that a neoplastic
process is suspected, the patient should be managed as if a low-grade squamous
intraepithelial lesion (LSIL) were present (see Recommendation 7, which follows)
(Bill). If a patient who has a diagnosis of ASCUS is at high risk (i.e., previous positive
Pap tests or poor adherence to follow-up), the option of colposcopy should be consid-
ered (Bill).
7. Several management options are available for patients who have LSIL. Follow up
with Pap tests every 4-6 months is used by many clinicians and is currently used in
countries outside the United States as an established method of management.
Patients managed in this way must be carefully selected and considered reliable for
follow-up. If repeat smears show persistent abnormalities, colposcopy and directed
biopsy are indicated (Bill). Colposcopy and directed biopsy of any abnormal area on
the ectocervix constitute another appropriate option (Bill).
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8. Women who have cytologic diagnosis of high-grade squamous intraepithelial
lesions (HSILs) or squamous cell carcinoma should undergo colposcopy and directed
biopsy (All).
9. No data are available to suggest that these guidelines to prevent cervical disease
should be modified for women on HAART.
HPV-associatedAnal Intraepithelial Neoplasia andAnal Cancer in HIV-infected,
Men Who Have Sex With Men
10. Evidence from several studies shows that HPV-positive men who have sex with
men are at increased risk for anal HSILs and might be at increased risk for anal cancer.
In view of this evidence, coupled with a recent cost-effectiveness analysis projecting
that screening and treatment for anal HSILs provide clinical benefits comparable to
other measures to prevent OIs in HIV-infected persons (80), anal cytology screening
of HIV-infected men who have sex with men might become a useful preventive meas-
ure in the near future. However, further studies of screening and treatment programs
for anal HSILs need to be carried out before recommendations for routine anal cytol-
ogy screening can be made.
Prevention of Recurrence
11. The risks for recurrence of squamous intraepithelial lesions and cervical cancer
after conventional therapy are increased among HIV-infected women. The prevention
of illness associated with recurrence depends on careful follow-up of patients after
treatment. Patients should be monitored with frequent cytologic screening and, when
indicated, with colposcopic examination for recurrent lesions (AI) (79).
12. In one recent study of HIV-infected women treated for HSILs using standard
therapy, low-dose intravaginal 5-fluorouracil (2 grams twice a week for 6 months)
reduced the short-term risk for recurrence and possibly the grade of recurrence (81).
However, clinical experience with this therapy is too limited to provide a recommen-
dation for routine use.
Special Considerations
Pregnant Women
13. Use of intravaginal 5-fluorouracil to prevent recurrent dysplasia is not recom-
mended during pregnancy.
Hepatitis C Virus Infection
Prevention of Exposure
1. The chief route of hepatitis C virus (HCV) transmission in the United States is
injection drug use. Because injection drug use is a complex behavior, clinicians should
assess the individual’s readiness to change this practice and encourage efforts to pro-
vide patient education and support directed at recovery.
Patients who inject drugs should be advised (82-84)--
* to stop using injection drugs (AIII); and
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to enter and complete a substance-abuse treatment program, including a relapse
prevention program (AIII).
If they are continuing to inject drugs, patients should be advised (Bill)
to never reuse or share syringes, needles, water, or drug preparation equipment;
if, nonetheless, injection equipment that has been used by other persons is
shared, to first clean the equipment with bleach and water as is recommended
for prevention of HIV;
to use only sterile syringes obtained from a reliable source (e.g., pharmacies or
syringe exchange programs);
to use sterile (e.g., boiled) water to prepare drugs; if not possible, to use clean
water from a reliable source (e.g., fresh tap water);
to use a new or disinfected container ("cooker") and a new filter ("cotton") to
prepare drugs;
to clean the injection site with a new alcohol swab before injection; and
to safely dispose of syringes after one use.
If they are continuing to use illegal drugs intranasally ("snorting"), patients should
be advised (Bill)
* to be aware that this practice has been associated with HCV transmission; and
to not share equipment (e.g., straws) with other users.
2. Persons considering tattooing or body piercing should be informed of potential
risks of acquiring bloodborne infections, which could be transmitted if equipment is
not sterile or if proper infection control procedures are not followed (e.g., washing
hands, using latex gloves, and cleaning and disinfecting surfaces) (84) (Bill).
3. To reduce risks for acquiring bloodborne infections, patients should be advised
not to share dental appliances, razors, or other personal care articles (Bill).
4. Although the efficiency of sexual transmission of HCV remains controversial,
safe-sexual practices should be encouraged, and barrier precautions (e.g., latex
condoms) are recommended to reduce the risk for exposure to sexually transmitted
pathogens (All).
Prevention of Disease
5. HIV-infected patients should be screened for HCV infection by using enzyme
immunoassays (EIAs) licensed for detection of antibody to HCV (anti-HCV)in blood
(Bill). Positive anti-HCV results should be verified with additional testing (i.e., recom-
binant immunoblot assay [RIBA’" or reverse transcriptase polymerase chain reaction
for HCV RNA). The presence of HCV RNA in blood might also be assessed in HIV-
infected persons with undetectable antibody but other evidence of chronic liver dis-
ease (e.g., unexplained elevated liver-specific enzymes) or when acute HCV infection
is suspected (CIII).
6. Persons coinfected with HIV and HCV should be advised not to drink excessive
amounts of alcohol (All). Avoiding alcohol altogether might be prudent because it is
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unclear whether even occasional moderate alcohol use (e.g., <12 ounces of beer or
<10 grams of alcohol per week) increases the incidence of cirrhosis among HCV-
infected persons (CIII).
7. Patients with chronic hepatitis C should be vaccinated against hepatitis A be-
cause a) the risk for fulminant hepatitis associated with hepatitis A appears increased
in HCV-coinfected persons; b) hepatitis A vaccine is safe for HIV-infected persons; and
c) although immunogenicity is reduced in patients with advanced HIV infection, more
than two thirds of patients develop protective antibody responses (Bill). Prevaccina-
tion screening for antibody to hepatitis A virus is cost-effective and therefore
recommended when >30% prevalence of hepatitis A virus antibody is expected in the
population being screened (e.g., persons >40 years of age) (85) (Bill).
8. HIV-HCV-coinfected patients have a higher incidence of chronic liver disease
than patients infected with HIV alone (86) and should be evaluated for chronic liver
disease and for the possible need for treatment (83). However, limited data exist
regarding the safety and efficacy of antiviral treatment of patients coinfected with HIV
and HCV. Moreover, because the optimal means of treating coinfected patients has not
been established and many HIV-infected patients have conditions that complicate
therapy (e.g., depression or illicit drug use), this care should occur in a clinical trial or
be coordinated by providers with experience treating both HIV and HCV infections
(Bill).
9. In some studies, the incidence of antiretroviral-associated liver enzyme eleva-
tions has been increased in patients coinfected with HIV and HCV (87); such increases
might not require treatment modifications. Thus, although liver enzymes should be
carefully monitored, HAART should not be routinely withheld from patients coinfected
with HIV and HCV (Dill). However, coinfected patients initiating antiretroviral therapy
might have an inflammatory reaction that mimics an exacerbation of underlying liver
disease. In this situation, careful monitoring of liver function is required.
Prevention ofRecurrence
10. If the serum HCV RNA level becomes undetectable during HCV therapy and
remains undetectable for 6 months after HCV therapy is stopped (sustained virologic
response), >90% of HIV-uninfected patients with hepatitis C will remain HCV RNA
negative for >5 years and have improved liver histology (88). For HIV-HCV-coinfected
patients, the durability of treatment response and requirement for maintenance ther-
apy are unknown.
Special Considerations
Children
11. Children born to women coinfected with HIV and HCV should be tested for HCV
infection (82) (BI). In children with perinatal HCV infection, maternal HCV antibody can
persist for up to 18 months, and HCV RNA can be intermittently undetectable. Thus,
testing should be performed at or after 2 years of age. If earlier diagnosis is needed,
HCV RNA should be assessed in more than one infant blood specimen obtained after
1 month of age. The average rate of HCV infection among infants born to coinfected
women is approximately 15% (range, 5-36%) (89). Data are limited on the natural
history and treatment of HCV infection in children.
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TABLE 1. Prophylaxis to prevent first episode of opportunistic disease in adults and
adolescents infected with human immunodeficiency virus
Preventive Regimens
Indication First Choice
CD4+ count <200/L
or oropharyngeal
candidiasis
Trimethoprim-
sulfamethoxazole
(TMP-SMZ), DS po
q.d. (AI)
TMP-SMZ, SS po
q.d. (AI)
.P,at..hogen
I. Strongly
recommended as
standard of care
Pneumocystis carinii*
Alternatives
Dapsone, 50 mg po
b.i.d, or 100 mg po
q.d. (BI); dapsone,
50 mg po q.d. plus
pyrimethamine,
50 mg po q.w. plus
leucovorin, 25 mg po
q.w. (BI); dapsone,
200 mg po plus
pyrimethamine,
75 mg po plus
leucovorin, 25 mg po
q.w. (BI); aerosolized
pentamidine, 300 mg
q.m. via
Respirgard II
nebulizer (BI);
atovaquone, 1500 mg
po q.d. (BI);
TMP-SMZ, DS po
t.i.w. (BI)
Mycobacterium
tuberculosis
Isoniazid-sensitivet
prior positive TST
result without
treatment or contact
with case of active
tuberculosis
TST reaction >5mm or Isoniazid, 300 mg po
plus pyridoxine,
50 mg po q.d. x9 mo
(All) or isoniazid,
900 mg po plus
pyridoxine, 100 mg
po b.i.w, x 9 mo (BI);
rifampin, 600 mg plus
pyrazinamide,
20 mg/kg po q.d. x 2
mo (AI)
Rifabutin 300 mg po
q.d. plus
pyrazinamide,
20 mg/kg po q.d. x 2
mo (Bill); rifampin
600 mg po q.d. x 4
mo (Bill)
Isoniazid-resista nt Same; high
probability of
exposure to
isoniazid-resistant
tuberculosis
Rifampin 600 mg plus
pyrazinamide,
20 mg/kg po q.d. x 2
mo (AI)
Rifabutin, 300 mg
plus pyrazinamide
20 mg/kg po q.d. x 2
mo (Bill); rifampin,
600 mg po q.d. x 4
mo (Bill); Rifabutin,
300 mg po q.d. x 4
mo (CIII)
Multidrug-(isoniazid
and rifampin)
resistant
Same; high
probability of
exposure to
multidrug-resistant
tuberculosis
Choice of drugs
requires consultation
with public health
authorities
None
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TABLE 1. Prophylaxis to prevent first episode of opportunistic disease in adults and
adolescents infected with human immunodeficiency virus---Continued
Indication
IgG antibody to
Toxoplasma and
CD4+ count <100/L
Preventive Regimens
First Choice
TMP-SMZ, DS po
q.d. (All)
Pathogen
Toxoplasma gondii
Alternatives
TMP-SMZ, SS po
q.d. (Bill): dapsone,
50 mg po q.d. plus
pyrimethamine,
50 mg po q.w. plus
leukovorin, 25 mg po
q.w. (BI); atovaquone,
1500 mg po q.d. with
or without
pyrimethamine,
25 mg po q.d. plus
leukovorin, 10 mg po
q.d. (CIII)
Mycobacterium
avium complex
CD4+ count <50/L Azithromycin,
1,200 mg po q.w., (AI)
or clarithromycin,
500 mg po b.i.d. (AI)
Rifabutin, 300 mg po
q.d. (BI);
azithromycin,
1,200 mg po q.w. plus
rifabutin, 300 mg po
q.d. (CI)
Varicella zoster virus
(VZV)
Significant exposure
to chickenpox or
shingles for patients
who have no history
of either condition or,
if available, negative
antibody to VZV
Varicella zoster
immune globulin
(VZIG), 5 vials
(1.25 mL each) im,
administered <96 h
after exposure, ideally
within 48 h (AIII)
II. Generally
recommended
Streptococcus
pneurnoniae**
Hepatitis B virustt
All patients
All susceptible
(anti-HBc-negative)
patients
Pneumococcal
vaccine, 0.5 mL im
(CD4+ >200/L [BII];
CD4+ <200/L [CIII])-
might reimmunize if
initial immunization
was given when CD4+
<200/L and if CD4+
increases to >200/L
on HAART(CIII)
None
Hepatitis B vaccine: None
3 doses (BII)
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TABLE 1. Prophylaxis to prevent first episode of opportunistic disease in adults and
adolescents infected with human immunodeficiency virus--Continued
Preventive Regimens
Pathogen
Influenza virustt
Indication First Choice Alternatives
All patients (annually, Whole or split virus, Rimantadine, 100 mg
before influenza 0.5 mL im/yr (Bill) po b.i.d. (CIII), or
season) amantadine, 100 mg
po b.i.d. (CIII)
Hepatitis A virus
III. Not routinely
indicated
Bacteria
All susceptible
(anti-HAV-negative)
patients With chronic
hepatitis C
Neutropenia
Hepatitis A vaccine: None
two doses (Bill)
Granulocyte-
colony-stimulating
factor (G-CSF),
5-10 [ag/kg sc q.d. x
2-4w or granulocyte-
macrophage
colony-stimulating
factor (GM-CSF),
250 g/m2 iv over 2 h
q.d. x 2-4 w (CII)
None
Cryptococcus CD4+ count <50/L Fluconazole,
neoformans 100-200 mg po q.d.
(CI)
Itraconazole, 200 mg
po q.d. (CIII)
Histoplasma CD4+ count <100/[aL, Itraconazole capsule, None
capsulatum endemic geographic 200 mg po q.d.(CI)
area
Cytomegalovirus CD4+ count <50/L Oral ganciclovir, g None
(CMV) and CMV antibody po t.i.d. (CI)
positivity
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA)
approval or approved labeling for the particular products or indications in question. Specifically, the terms
"safe" and "effective" might not be synonymous with the FDA-defined legal standards for product approval.
The Respirgard II nebulizer is manufactured by Marquest, Englewood, Colorado. Letters and Roman numerals
in parentheses after regimens indicate the strength of the recommendation and the quality of evidence
supporting it (see Box, page 3).
ABBREVIATIONS: Anti-HBc antibody to hepatitis B core antigen; b.i.w.= twice a week; DS double-strength
tablet; HAART highly active antiretroviral therapy; HAV hepatitis A virus; HIV human immunodeficiency
virus; im intramuscular; iv intravenous; po by mouth; q.d. daily; q.m. monthly; q.w. weekly;
SS= single-strength tablet; t.i.w. three times a week; TMP-SMZ trimethoprim-sulfamethoxazole;
sc subcutaneous; and TST tuberculin skin test.
* Prophylaxis should also be considered for persons with a CD4+ percentage of <14%, for persons with a
history of an AIDS-defining illness, and possibly for those with CD4+ counts >200 but <250 cells/L.
TMP-SMZ also reduces the frequency of toxoplasmosis and some bacterial infections. Patients receiving
dapsone should be tested for glucose-6 phosphate dehydrogenase deficiency. A dosage of 50 mg q.d.
is probably less effective than that of 100 mg q.d. The efficacy of parenteral pentamidine (e.g.,
4 mg/kg/month) is uncertain. Fansidar (sulfadoxine-pyrimethamine) is rarely used because of severe
hypersensitivity reactions. Patients who are being administered therapy for toxoplasmosis with
sulfadiazine-pyrimethamine are protected against Pneumocystis carinii pneumonia and do not need
additional prophylaxis against PCP.
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Directly observed therapy is recommended for isoniazid, 900 mg b.i.w.; isoniazid regimens should include
pyridoxine to prevent peripheral neuropathy. Rifampin should not be administered concurrently with
protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Rifabutin should not be given with
hard-gel saquinavir or delavirdine; caution is also advised when the drug is coadministered with soft-gel
saquinavir. Rifabutin may be administered at a reduced dose (150 mg q.d.) with indinavir, nelfinavir, or
amprenavir; at a reduced dose of 150 mg q.o.d. (or 150 mg three times weekly) with ritonavir; or at an
increased dose (450 mg q.d.) with efavirenz; information is lacking regarding coadministration of rifabutin
with nevirapine. Exposure to multidrug-resistant tuberculosis might require prophylaxis with two drugs;
consult public health authorities. Possible regimens include pyrazinamide plus either ethambutol or a
fluoroquinolone.
Protection against toxoplasmosis is provided by TMP-SMZ, dapsone plus pyrimethamine, and possibly
by atovaquone. Atovaquone may be used with or without pyrimethamine. Pyrimethamine alone probably
provides little, if any, protection.
See footnote t regarding use of rifabutin with protease inhibitors or nonnucleoside reverse transcriptase
inhibitors.
Vaccination should be offered to persons who have a CD4+ T-lymphocyte count <200 cells/rtL, although
the efficacy might be diminished. Revaccination 5 years after the first dose or sooner if the initial
immunization was given when the CD4+ count was <200 cells/rtL and the CD4+ count has increased to
>200 cells/tL on HAART is considered optional. Some authorities are concerned that immunizations might
stimulate the replication of HIV. However, one study showed no adverse effect of pneumococcal
vaccination on patient survival (McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW, and the
Adult/Adolescent Spectrum of Disease Group. Effects of antiretroviral therapy and opportunistic illness
primary chemoprophylaxis on survival after AIDS diagnosis. AIDS 1999 [in press]).
These immunizations or chemoprophylactic regimens do not target pathogens traditionally classified as
opportunistic but should be considered for use in HIV-infected patients as indicated. Data are inadequate
concerning clinical benefit of these vaccines in this population, although it is logical to assume that those
patients who develop antibody responses will derive some protection. Some authorities are concerned
that immunizations might stimulate HIV replication, although for influenza vaccination, a large
observational study of HIV-infected persons in clinical care showed no adverse effect of this vaccine,
including multiple doses, on patient survival (J. Ward, CDC, personal communication). Hepatitis B vaccine
has been recommended for all children, and adolescents and for all adults with risk factors for hepatitis
B virus (HBV). Rimantadine and amantadine are appropriate during outbreaks of influenza A. Because
of the theoretical concern that increases in HIV plasma RNA following vaccination during pregnancy
might increase the risk of perinatal transmission of HIV, providers may wish to defer vaccination until
after antiretroviral therapy is initiated. For additional information regarding vaccination against hepatitis
A and B and vaccination and antiviral therapy against influenza see CDC. Prevention of hepatitis A through
active or passive immunization: recommendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR 1996;45(No. RR-15); CDC. Hepatitis B virus: a comprehensive strategy for eliminating
transmission in the United States through universal childhood vaccination: recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR 1991;40(No. RR-13); and CDC. Prevention
and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR 1999;48(No. RR-4).
In a few unusual occupational or other circumstances, prophylaxis should be considered; consult a
specialist.
Acyclovir is not protective against CMV. Valacyclovir is not recommended because of an unexplained
trend toward increased mortality observed in persons with AIDS who were being administered this drug
for prevention of CMV disease.
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TABLE 2. Prophylaxis to prevent recurrence of opportunistic disease (after
chemotherapy for acute disease) in adults and adolescents infected with human
immunodeficiency virus
Preventive Regimens
Patholen Indication First Choice
I. Recommended for life as standard of care
Pneumocystis carinii Prior R carinfi
pneumonia
Alternatives
Trimethoprim- Dapsone, 50 mg po b.i.d.
sulfamethoxazole or 100 mg po q.d. (BI);
(TMP-SMZ), DS po q.d. dapsone, 50 mg po q.d.
(AI); plus pyrimethamine,
50 mg po q.w. plus
TMP-SMZ SS po q.d. leucovorin, 25 mg po q.w.
(AI) (BI); dapsone, 200 mg po
plus pyrimethamine,
75 mg po plus leucovorin,
25 mg po q.w. (BI);
aerosolized pentamidine,
300 mg q.m. via
Respirgard I1’" nebulizer
(BI); atovaquone,
1500 mg po q.d. (BI);
TMP-SMZ, DS po t.i.w.
(CI)
Toxoplasma gondii* Prior toxoplasmic
encephalitis
Sulfadiazine, 500-1,000
mg po q.i.d, plus
pyrimethamine, 25-75
mg po q.d. plus
leucovorin, 10-25 mg po
q.d. (AI)
Clindamycin, 300-450 mg
po q 6-8 h plus
pyrimethamine,
25-75 mg po q.d. plus
leucovorin, 10-25 mg po
q.d. (BI); atovaquone,
750 mg po q. 6-12 h with
or without
pyrimethamine, 25 mg po
q.d. plus leucovorin,
10 mg po q.d. (CIII)
Mycobacterium
avium complex t
Documented
disseminated
disease
Clarithromycin, 500 mg Azithromycin, 500 mg po
po b.i.d. (AI) plus q.d. (All) plus ethambutol,
ethambutol, 15 mg/kg po 15 mg/kg po q.d.(AII);
q.d.(AII); with or without with or without rifabutin,
rifabutin, 300 mg po q.d. 300 mg po q.d.(CI)
(CI)
Cytomegalovirus Prior end-organ
disease
Ganciclovir, 5-6 mg/kg iv Cidofovir, 5 mg/kg iv
5-7 days/wk or 1,000 mg q.o.w, with probenecid
po t.i.d. (AI); or foscarnet, 2 grams po 3 hours
90-120 mg/kg iv q.d. (AI); before the dose followed
or (for retinitis) by gram po given
ganciclovir 2 hours after the dose,
sustained-release implant and 1 gram po 8 hours
q 6-9 months plus after the dose (total of
ganciclovir, 1.0-1.5 g po 4 grams)(AI). Fomivirsen
t.i.d. (AI) vial (330 g)injected
into the vitreous, then
repeated every 2-4 wks
(AI)
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TABLE 2. Prophylaxis to prevent recurrence of opportunistic disease (after
chemotherapy for acute disease) in adults and adolescents infected with human
immunodeficiency virus Continued
Preventive Regimens
Patholen Indication First Choice,
Cryptococcus Documented Fluconazole, 200 mg po
neoformans disease q.d. (AI)
Alternatives
Amphotericin B,
0.6-1.0 mg/kg iv
q.w.-t.i.w. (AI);
itraconazole, 200 mg po
q.d. (BI)
Histoplasrna Documented
capsulatum disease
Itraconazole capsule,
200 mg po b.i.d. (AI)
Amphotericin B,
1.0 mg/kg iv q.w. (AI)
Coccidioides Documented
immitis disease
Fluconazole, 400 mg po
q.d. (All)
Amphotericin B,
1.0 mg/kg iv q.w. (AI);
itraconazole, 200 mg po
b.i.d. (All)
Salmonella species, Bacteremia Ciprofloxacin, 500 mg po Antibiotic
(non-typh) b.i.d, for several months chemoprophylaxis with
(BII) another active agent (CIII)
II. Recommended only if subsequent episodes are frequent or severe
Herpes simplex virus Frequent/severe Acyclovir, 200 mg po t.i.d. Valacyclovir, 500 rng po
recurrences or 400 mg po b.i.d.(AI) b.i.d. (CIII)
Famciclovir 500 mg po
b.i.d. (AI)
Candida Frequent/severe
(oropharyngeal or recurrences
vaginal)
Fluconazole 100-200 mg
po q.d. (CI)
Itraconazole solution,
200 mg po q.d. (CI);
ketoconazole, 200 mg po
q.d. (CIII)
Candida (esophageal) Frequent/severe Fluconazole 100-200 mg Itraconazole solution,
recurrences po q.d. (BI) 200 mg po q.d. (BI);
ketoconazole, 200 mg po
q.d. (CIII)
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA)
approval or approved labeling for the particular products or indications in question. Specifically, the terms
"safe" and "effective" might not be synonymous with the FDA-defined legal standards for product approval.
The Respirgard II nebulizer is manufactured by Marquest, Englewood, Colorado. Letters and Roman
numerals in parentheses after regimens indicate the strength of the recommendation and the quality of
evidence supporting it (see Box, page 3).
ABBREVIATIONS" b.i.d. twice a day; DS double-strength tablet; po by mouth; q.d. daily; q.m. monthly;
q.w. weekly; q.o.w. every other week; SS single-strength tablet; t.i.d. three times a day; t.i.w. three
times a week; and TMP-SMZ trimethoprim-sulfamethoxazole.
*Pyrimethamine-sulfadiazine confers protection against PCP as well as toxoplasmosis; clindamycin-
pyrimethamine does not.
Many multiple-drug regimens are poorly tolerated. Drug interactions (e.g., those seen with clarithromycin
and rifabutin) can be problematic; rifabutin has been associated with uveitis, especially when administered
at daily doses of >300 mg or concurrently with fluconazole or clarithromycin. Rifabutin should not be
administered concurrently with hard-gel saquinavir or delavirdine; caution is also advised when the drug
is coadministered with soft-gel saquinavir. Rifabutin may be administered at reduced dose (150 mg q.d.
with indinavir, nelfinavir, or amprenavir; or 150 mg q.o.d, with ritonavir) or at increased dose (450 mg q.d.)
with efavirenz (CDC. Prevention and treatment of tuberculosis among patients infected with human immu-
nodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47[RR-20]). Information
is lacking regarding coadministration of rifabutin with nevirapine.
Efficacy of eradication of Salmonella has been demonstrated only for ciprofloxacin.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 491999 USPHS/IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS
TABLE 3. Effects of food on drugs used to prevent opportunistic infections
)rug Food Effect Recommendation
Atovaquone Bioavailability increased up to Administer with food.
threefold with high-fat meal.
Ganciclovir (capsules) High-fat meal results in 22%
increase in the area under the
curve (AUC).
Administer with food.
Itraconazole (capsules) Significant increase in
bioavailability when taken with a
full meal. Grapefruit juice results
in 30% decrease in itraconazole
AUC.
Administer with food; avoid
grapefruit juice or increased
itraconazole dose might be
necessary.
Itraconazole (solution) 31% increase in AUC when taken Take without food if possible.
under fasting conditions.
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TABLE 4. Effects of medications on drugs used to prevent opportunistic infections
Affected drug Interacting drug(s)’ Mechani’sm/Effect Recommendation
Atovaquone Ri’fampin induction of Concentrations might’
metabolism-- not be therapeutic;
decreased drug levels avoid combination or
increase atovaquone
dose.
Clarithromycin Ritonavir Inhibition of
metabolism
increased drug levels
by 77%
No adjustment needed
in normal renal
function; adjust if
creatinine clearance is
<30.
Clarithromycin Nevirapine Induction of Effect on
metabolism--- Mycobacterium avium
decrease in prophylaxis might be
clarithromycin area decreased; monitor
under the curve (AUC) closely.
by 35%, increase in
AUC of 14-OH
clarithromycin by 27%
Ketoconazole Antacids, didanosine,
H2-blockers, proton
pump inhibitors
Increase in gastric pH
that impairs
absorption of
ketoconazole
Avoid use of
ketoconazole with
pH-raising agents or
use alternative
antifungal drug.
Quinolone antibiotics Didanosine, antacids, Chelation that results
(ciprofloxacin, iron products, calcium in marked decrease in
levofloxacin, ofloxacin) products, sucralfate quinolone drug levels
Administer interacting
drug at least 2 hours
after quinolone.
Rifabutin Fluconazole Inhibition of Monitor for rifabutin
metabolism marked toxicity such as uveitis,
increase in rifabutin nausea, neutropenia.
drug levels
Rifabutin Efavirenz Induction of
metabolism
significant decrease in
rifabutin AUC
Increase rifabutin dose
to 450 mg daily.
Rifabutin Ritonavir, saquinavir,
indinavir, nelfinavir,
amprenavir,
delavirdine
Inhibition of Contraindicated with
metabolism marked hard-gel saquinavir
increase in rifabutin (caution also advised
drug levels with soft-gel
saquinavir) and
delavirdine; use
1/2 dose (150 mg daily),
with indinavir,
nelfinavir, amprenavir;
1/4 dose (150 mg every
other day) with
ritonavir.
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TABLE 5. Effects of opportunistic infection medications on drugs commonly
administered to persons infected with human immunodeficiency virus
Affected drug Interacting drug(s) Mechanism/Effect Recommendation
Indinavir, saquinavir, Rifampin Induction of Avoid concomitant use.
ritonavir, nelfinavir, metabolism marked
amprenavir decrease in protease
inhibitor drug levels
Delavirdine, Rifampin
nevirapine, efavirenz
Induction of
metabolism marked
decrease in drug levels
Avoid concomitant use.
Saquinavir (hard-gel), Rifabutin
delavirdine
Induction of
metabolism marked
decrease in drug levels
Avoid concomitant use.
Terfenadine,
astemizole, cisapride
Ketoconazole
Itraconazole
Fluconazole
Clarithromycin
Inhibition of
metabolism
Cardiotoxic
life-threatening effects
possible; avoid
concomitant use.
Didanosine (ddl) Ganciclovir Increases ddl area Clinical significance
under the curve (AUC) unknown; monitor for
by approximately 100% ddl-related adverse
effects.
TABLE 6. Adverse effects of opportunistic infection medications used in the
management of human immunodeficiency virus infection
Bone marrow suppression Cidofovir, dapsone, ganciclovir, pyrimethamine, rifabutin,
sulfadiazine, trimethoprim-sulfamethoxazole, trimetrexate
Diarrhea Atovaquone, clindamycin
Hepatotoxicity Clarithromycin, fluconazole, isoniazid, itraconazole,
ketoconazole, pyrazinamide, rifabutin, rifampin
Nephrotoxicity Amphotericin B, cidofovir, foscarnet, pentamidine
Ocular effects Cidofovir, ethambutol, rifabutin
Pancreatitis Pentamidine, trimethoprim-sulfamethoxazole
Peripheral neuropathy Isoniazid
Skin rash Atovaquone, dapsone, sulfadiazine,
trimethoprim-su Ifamethoxazo le
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TABLE 7. Dosages of drugs for primary prevention or maintenance therapy for persons
with opportunistic infections and renal insufficiency
Drug
Acyclovir
Cidofovir
Ciprofloxacin
Clarithromycin
Famciclovir
Fluconazole
Foscarnet
Ganciclovir
Normal Dosage
200 mg po t.i.d.
400 mg po q. 12 h
800 mg po q. 4 h
800 mg po q. 4 h
5 mg/kg iv q.o.w.
(with probenecid)
500 mg po q. 12 h
500 mg b.i.d.
500 mg po q. 12 h
50-400mg po q.d.
90-120 mg/kg
iv q.d.
Oral:
gram po t.i.d.
IV:
5 mg/kg q.d. or
6 mg/kg q.d. x
5 days/week
DS q.d.
DS t.i.w.
SS q.d.
Trimethoprim-
sulfamethoxazole
CrCI
(ml/min/1.73m2)
<10
<10
10-25
<10
Increase in serum
creatinine of
0.3-0.4 above
baseline
Increase in serum
creatinine of
0.5 above
baseline or
3+ proteinuria
30-50
<30
<30
20-39
<20
10-50
<10
Dialysis
CrCI*
>1.4
1.0-1.4
0.8-1.0
0.6-0.8
0.5-0.6
0.4-0.5
<0.4
50-69
25-49
10-24
<10
50-69
25-49
10-24
<10
<30
Adjusted dose
200 mg q. 12 h
200 mg q. 12 h
800 mg q. 8 h
800 mg q. 12 h
3 mg/kg
Discontinue.
250-500 mg q. 12 h
250-500 mg q. 18 h
/2 dose (or double interval)
250 mg q. 12 h
250 mg q. 24 h
1/2 dose
1/4 dose
Full dose after dialysis
Low dose
90 mg q. 24 h
70 mg q. 24 h
50 mg q. 24 h
80 mg q. 48 h
60 mg q. 48 h
50 mg q. 48h
Not recommended
High dose
120 mg q. 24 h
90 mg q. 24h
65 mg q. 24 h
105 mg q. 48 h
80mg q. 48h
65 mg q. 48 h
Not recommended
1,500 mg q.d. or 500 mg t.i.d.
1,000 mg q.d. or 500 mg b.i.d.
500 mg q.d.
500 mg t.i.w, after dialysis
2.5 mg/kg q. 24 h
1.25 mg/kg q. 24 h
0.625 mg/kg q. 48 h
0.625 mg/kg t.i.w.
1/2 dose
ABBREVIATIONS: b.i.d. twice daily; CrCI creatinine clearance; DS double-strength tablet; iv
intravenous; I.d. loading dose; q.d. daily; q.o.w. every other week; SS single-strength tablet;
t.i.d. three times daily; t.i.w. three times a week.
*Creatinine clearance for foscarnet is expressed as ml/min/kg.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOI,OGY 531999 USPHS/IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS
TABLE 8. Wholesale acquisition costs of agents recommended for the prevention of
opportunistic infections in adults infected with human immunodeficiency virus
Opportunistic
pathogen
Pneum)cystis c’rinii
Drug/vaccine Dose
Tr’imethoprim- 160/800’mg q.d.
sulfamethoxazole
Dapsone 100 mg q.d.
Aerosolized pentamidine 300 mg q.m.
Atovaquone 1500 mg q.d.
Annual cost
per patient
$60
$72
$,85
$10,647
Mycobacterium
avium complex
Clarithromycin 500 mg b.i.d.
Azithromycin 1,200 mg q.w.
Rifabutin 300 mg q.d.
$2,347
$1,635
$3,352
Cytomegalovirus Ganciclovir (po)
Ganciclovir implant*
Ganciclovir (iv)
Foscarnet (iv)
Cidofovir (iv)
Fomivirsen (intravitreal)
1,000 mg t.i.d.
5mg/kg q.d.
90-120 mg/kg q.d.
375 mg q.o.w.
vial every 4 wks
$17,269
$5,000
$9,113
$27,960-36,770
$19,812
$12,000
Mycobacterium
tuberculosis
Isoniazidt
Rifampin
Pyrazinamide
Ethambutol
300 mg q.d. $23
600 mg q.d. $1,540
1,500 mg q.d. $1,005
900 mg q.d. $1,527
Fungi Fluconazole
Itraconazole capsules
Itraconazole solution
Ketoconazole
200 mg q.d. $4,267
200 mg q.d. $4,893
200 mg q.d. $5,129
200 mg q.d. $1,230
Herpes simplex virus Acyclovir
Famciclovir
Valacyclovir
400 mg b.i.d. $1,300
500 mg b.i.d. $4,826
500 mg b.i.d. $1,435
Toxoplasma gondii Pyrimethamine 50 mg q.w. $45
Leucovorin 25 mg q.w. $1,248
Sulfadiazine 500 mg q.i.d. $1,421
Streptococcus 23-valent pneumococcal 0.5 ml im x $13
pneumoniae vaccine
Influenza virus Influenza vaccine 0.5 ml im x $5
Hepatitis B virus Recombinant hepatitis B 10-20tg im x 3 $195
Hepatitis A virus Hepatitis A vaccine 1.0 ml im x 2 $120
Bacterial infections G-CSF 300 #g t.i.w. $25,780
Varicella zoster virus VZIG 5 vials (6.25 ml) $560
ABBREVIATIONS: b.i.d twice daily; G-CSF granulocyte-colony-stimulating factor; iv intravenous; im
intramuscular; po b mouth; q.d. daily; q.o.w. every other week; q.w. once a week; t.i.d. three
times daily; t.i.w. three times a week; VZlG varicella zoster immune globulin.
Implant generally lasts 6-9 months.
Cost for 9 months of therapy.
Source: Medical Economics. Drug topics red book. Montvale, New Jersey: Medical Economics Inc., 1999.
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TABLE 9. Immunologic categories for human immunodeficiency virus-infected
children based on age-specific CD4+ T-lymphocyte counts and percentage of total
lymphocytes*
Immunologic category
1. No evidence of suppression
2. Evidence of moderate
suppression
3. Severe suppression
Age
<12 month.s.. 1,5 year.s 6-12 year.s
cells/gL (%) cells/L (%) cells/L (%)
>1,500 (>25) z1,000 (z2’5) z500 1z25)
750-1,499 (15-24) 500-999 (15-24) 200-499 (15-24)
<750 (<15) <500 (<15) <200 (<15)
*dapted from CDC. i994 revised classification"’system for human immunodeficiency virus
infection in children less than 13 years of age. MMWR 1994;43(No. RR-12).
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TABLE 10. Recommended immunization schedule for human immunodeficiency
virus-infected children*
Age 1 24
Vaccine Birth mo mos
Recommendations for these vaccines are the same as those for immunocompetent
Hepatitis B IHep B-1
Diphtheria,
Hep B’3....:
Tetanus, DTaP IDTP DTaP
Pertussis
Haemophilus
influenzae
type b*"
2 4 6 12 15 18 4-6 11-12 14-16
mos mos mos mos mos mos yrs yrs yrs
Hib [. Hib
children.
Hep B-2
DTaP DTaP
Hib Hib
Recommendations for these vaccines differ from those for immunocompetent children. ,
Do not
suppres
Polio
tt
Measles, Mumps,
Rubella
Influenza
Streptococcus
pneumoniae’*"
Varicella*"
Rotavirus
IPV IPV IPV IPV
ive to sverely in muno-
;ed (Cat,,gory 3) children. MMR MMR
Influenza (a dose is requ’red every year)
Pneumo-
coccal
Give onl y, to asy ptomatic nonimlnunosul pressed
(Category 1)children. COtaTRAINEICATED in Varicella all other HIV-inflcted.chil(Iren.
NOTES: Modified from the immunization schedule for immunocompetent children. This schedule also applies
to children born to HIV-infected mothers whose HIV infection status has not been determined. Once a child
is known not to be HIV-infected, the schedule for immunocompetent children applies. This schedule indicates
the recommended age for routine administration of currently licensed childhood vaccines. Some combination
vaccines are available and may be used whenever administration of all components of the vaccine is indicated.
Providers should consult the manufacturers’ package inserts for detailed recommendations.
*Vaccines are listed under the routinely recommended ages. Bars indicate range of acceptable ages for
vaccination. Shaded bar indicates catch-up vaccination: at 11-12 years of age, hepatitis B vaccine should
be administered to children not previously vaccinated.
Infants born to lHBSA_o-necative mothers should rec,ve 2.5 g of Merck vaccine (Recombivax HB (R)) or
10 pg of SmithKline Bechm (SB) vaccine (Engerix-B). The 2nd dose should be administered >1 month
after the 1st dose.
Infants born to HBsAo-.oositive mothers should receive 0.5 mL of hepatitis immune globulin (HBIG)
within 12 ours of brth and either 5g of Merck vaccine (Recombivax HB or 10 g of SB. vaccine
(Engerix-B) at a separate site. The 2nd dose is recommended at 1-2 months of age and the 3rd dose
at 6 months of age.
Infants born to,mothers whose HBsAg status is unknown should receive either 5 pg of Merck vaccine
(Recombivax HB or 10 pg of SB vaccine (Engerix-B) within 12 hours of birth. The 2nd dose of vaccine
is recommended at month of age and the 3rd dose at 6 months of age. Blood should be drawn at the
time of delivery to determine the mother’s HBsAg status; if it is positive, the infant should receive HBIG
as soon as possible (no later than week of age). The dosage and timing of subsequent vaccine doses
should be based upon the mother’s HBsAg status.
Children and adolescents who have not been vaccinated against hepatitis B in infancy can begin the
series during any childhood visit. Those who have not previously received 3 doses of hepatitis B vaccine
should initiate or complete the series during the 11 to 12-year-old visit. The 2nd dose should be
administered at least month after the 1st dose, and the 3rd dose should be administered at least
4 months after the 1st dose and at least 2 months after the 2nd dose.
DTaP (diphtheria and tetanus toxoids and acellular pertussis vaccine) is the preferred vaccine for all
doses in the vaccination series, including completion of the series in children who have received >1 dose
of whole-cell DTP vaccine. The 4th dose of DTaP may be administered as early as 12 months of age,
provided 6 months have elapsed since the 3rd dose, and if the child is considered unlikely to return at
15-18 months of age. Td (tetanus and diphtheria toxoids, adsorbed, for adult use) is recommended at
11-12 years of ageif at least 5 years have elapsed since the last dose of DTaP or DT. Subsequent routine
Td boosters are recommended every 10 years.
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**Three H. influenzae type b (Hib) conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHib(R))
(Merck) is administered at 2 and 4 months of age, a dose at 6 months is not required. After the primary
series has been completed any Hib conjugate vaccine may be used as a booster. tt Inactivated poliovirus vaccine (IPV) is the only polio vaccine recommended for HIV-infected persons and
their household contacts. Although the third dose of IPV is generally administered at 12-18 months, the
third dose of IPV has been approved to be administered as early as 6 months of age. Oral poliovirus
vaccine (OPV) should not be administerd to HIV-infected persons or their household contacts.
MMR should not be administered to severely immunocompromised children. HIV-infected children
without severe immunosupression should routinely receive their first dose of MMR as soon as possible
upon reaching the first birthday. Consideration should be given to administering the second dose of
MMR vaccine as soon as month (i.e., minimum 28 days) after the first dose, rather than waiting until
school entry.
Influenza virus vaccine should be administered to all HIV-infected children >6 months of age each year.
Children aged 6 months--8 years years who are receiving influenza vaccine for the first time should
receive two doses of split virus vaccine separated by at least month. In subsequent years, a single
dose of vaccine (split virus for persons s12 years of age, whole or split virus for persons >12 years of
age) should be administered each year. The dose of vaccine for children aged 6-35 months is 0.25 mL:
the dose for children aged 3 years is 0.5 mL.
***The 23-valent pneumococcal vaccine should be administered to HIV-infected children at 24 months of
age. Revaccination should generally be offered to HIV-infected children vaccinated 3-5 years (children
aged sl0 years) or >5 years (children aged >10 years) earlier. ttt Varicella zoster virus vaccine, 0.5 mL, is given as a subcutaneous dose between 12 months and 12 years
of a.ge; a second dose should be given 3 months later. The vaccine should be given only to asymptomatic,
non=mmunosuppressed children.
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TABLE 11. Prophylaxis to prevent first episode of opportunistic disease in infants and
children infected with human immunodeficiency virus
Pathogen
I. Strongly recommended as standard of care
Pneumocystis carinii* HIV-infected or
HIV-indeterminate,
infants aged 1-12 mo;
Preventive Regimens
Indication First Choice Alternatives
Trimethoprim-
su Ifamethoxazole
(TMP-SMZ), 150/750
mg/m2/d in 2 divided
HIV-infected children doses po t.i.w, on
aged 1-5 yr with CD4+ consecutive days (All)
count <500/L or CD4+
percentage <15%;
HIV-infected children
aged 6-12 yr with
CD4+ count <200/L or
CD4+percentage <15%
Mycobacterium
tuberculosist
Isoniazid-sensitive TST reaction, >5mm
or prior positive TST
result without
treatment or contact
with case of active
tuberculosis
Ison iazid-resistant Same as above; high
probability of
exposure to
ison iazid-resistant
tuberculosis
Multidrug-(isoniazid Same as above; high
and rifampin) probability of
resistant exposure to
multidrug-resistant
tuberculosis
Mycobacterium avium For children aged
complext >6 yrs, CD4+ count
<50/lL; aged 2-6 yrs,
CD4+ count <75/L;
aged 1-2 yrs, CD4+
count <500/L; aged
<1 yr, CD4+ count
<750/L
Varicella zoster virus
Dapsone (children
aged >1 mo), 2 mg/kg
(max 100 mg) po q.d.
or 4 mg/kg (max
200 mg) po q.w. (CII);
aerosolized
pentamidine (children
Acceptable alternative aged >5 yr), 300 mg
dosage schedules: (All) q.m. via Respirgard
IITM nebulizer (CIII);
Single dose po atovaquone (children
t.i.w, on aged 1-3 mo. and
consecutive days; >24 mo., 30 mg/kg po
q.d.; children aged
2 divided doses po 4-24 mo., 45 mg/kg po
q.d.; 2 divided q.d.) (CII)
doses po t.i.w, on
alternate days
Isoniazid 10-15 mg/kg
(max 300 mg) po q.d.
x 9 mo (All) or
20-30 mg/kg (max
900 mg) po b.i.w, x 9
mo (Bill)
Rifampin, 10-20
mg/kg (max 600 mg)
po q.d. x 4-6 mo (Bill)
Rifampin,
10-20 mg/kg (max
600 mg) po q.d. x
4-6 mo (Bill)
Uncertain
Choice of drugs
requires consultation
with public health
authorities
None
Clarithromycin, Azithromycin, 5 mg/kg
7.5 mg/kg (max (max 250 mg) po q.d.
500 mg) po b.i.d. (All), (All); children aged
or azithromycin, >6 yrs, rifabutin,
20 mg/kg (max 300 mg po q.d. (BI)
1,200 mg) po q.w. (All)
Significant exposure Varicella zoster
to varicella or shingles immune globulin
with no history of (VZIG), vial
chickenpox or shingles (1.25 mL)/10 kg (max
5 vials)im,
administered <96 hrs
after exposure, ideally
within 48 hrs (All)
None
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TABLE 11. Prophylaxis to prevent first episode of opportunistic disease in infants and
children infected with human immunodeficiency virus Continued
Preventive Regimens
Pathogen Indication First Choice Alternatives
Vaccine-preventable HIV exposure/infection Routine None
pathogens immunizations (.see
Table 10)
II. Generally recommended
Toxoplasma gondil IgG antibody to
Toxoplasma
and severe
imrnunosuppression
TMP-SMZ,
150/750 mg/m2/d in 2
divided doses po q.d.
(Bill)
Dapsone (children
aged >1 mo), 2 mg/kg
or 15 mg/m2 (max
25 mg) po q.d. plus
pyrimethamine,
mg/kg po q.d. plus
leucovorin, 5 mg po
every 3 days (Bill)
Varicella zoster virus
Influenza virus
HIV-infected children Varicella zoster
who are vaccine (see vaccine-
asymptomatic and not preventable
immunosuppressed pathogens section of
this table) (BII)
All patients (annually,
before influenza
season)
Influenza vaccine (see
vaccine-preventa ble
pathogens section of
this table) (Bill)
Atovaquone, (aged
1-3 mo. and >24 mo.,
30 mg/kg po q.d.;
aged 14-24 mo.
45 mg/kg po q.d.) (CIII)
None
Rimantadine or
amantadine (during
outbreaks of influenza
A); aged 1-9 yr,
5 mg/kg in 2 divided
doses po q.d.; aged
>10 yr, use adult
doses (CIII)
III. Not recommended for most children; indicated for use only in unusual circumstances
Invasive bacterial Hypogamma- IVIG (400mg/kg every None
infectionstt globulinemia (i.e., IgG 2-4 wks) (AI)
<400 mg/d L)
Cryptococcus
neoformans
Severe
mmunosuppression
Fluconazole, 3-6
mg/kg po q.d. (CII)
Itraconazole,
2-5 mg/kg po every
12-24 h (CII)
Histoplasma Severe Itraconazole, None
capsulatum immunosuppression, 2-5 mg/kg po every
endemic geographic 12-24 h (CIII)
area
Cytomegalovirus CMV antibody Oral ganciclovir None
(CMV) positivity and severe 30 mg/kg po t.i.d. (CII)
immunosuppression
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA)
approval or approved labeling for the particular products or indications in question. Specifically, the terms
"safe" and "effective" might not be synonymous with the FDA-defined legal standards for product approval.
The Respirgard I1"" nebulizer is manufactured by Marquest, Englewood, Colorado. Letters and Roman
numerals in parentheses after regimens indicate the strength of the recommendation and the quality of the
evidence supporting it (see Box, page 3).
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ABBREVIATIONS: b.i.w. twice a week; IVIG intravenous immune globulin; q.d. daily; q.m. monthly;
t.i.d. three times a day; t.i.w. three times a week.
* Daily TMP-SMZ reduces the frequency of some bacterial infections. TMP-SMZ, dapsone-pyrimethamine,
and possibly atovaquone (with or without pyrimethamine) appear to protect against toxoplasmosis,
although data have not been prospectively collected. When compared with weekly dapsone, daily
dapsone is associated with lower incidence of Pneurnocystis carinii pneumonia (PCP) but higher
hematologic toxicity and mortality (Mclntosh K, Cooper E, Xu J, et al. Toxicity and efficacy of daily vs.
weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with HIV. Ped
Infect Dis J 1999;18:432-9). The efficacy of parenteral pentamidine (e.g., 4 mg/kg q 2-4 wks) is
controversial. Patients receiving therapy for toxoplasmosis with sulfadiazine-pyrimethamine are
protected against PCP and do not need TMP-SMZ.
Significant drug interactions might occur between rifamycins (rifampin and rifabutin) and protease
inhibitors and nonnucleoside reverse transcriptase inhibitors. Consult a specialist.
Children routinely being administered intravenous immune globulin (IVIG) should receive VZIG if the
last dose of IVIG was administered >21 days before exposure.
I HIV-infected and HIV-exposed children should be immunized according to the childhood immunization
schedule in this report (Table 10), which has been adapted from the January-December 1999 schedule
recommended for immunocompetent children by the Advisory Committee on Immunization Practices,
the American Academy of Pediatrics, and the American Academy of Family Physicians. This schedule
differs from that for immunocompetent children in that inactivated poliovirus vaccine (IPV) replaces oral
poliovirus vaccine (OPV), and vaccination against influenza (Bill) and Streptococcus pneumoniae (BII)
should be offered. MMR should not be administered to severely immunocompromised children (Dill).
Vaccination against varicella is indicated only for asymptomatic nonimmunosuppressed children (BII),
and rotavirus vaccine is contraindicated in all HIV-infected children (EIII). Once an HIV-exposed child is
determined not to be HIV infected, the schedule for immunocompetent children applies.
** Protection against toxoplasmosis isprovided by the preferred antipneumocystis regimens and possibly
by atovaquone. Atovaquone may be.used with or without pyrimethamine. Pyrimethamine alone probably
provides little, if any, protection (for definition of severe immunosuppression, see Table 9).
tt Respiratory syncytial virus (RSV) IVIG (750 mg/kg), not monoclonal RSV antibody, may be substituted
for IVIG during the RSV season to provide broad antiinfective protection, if this product is available.
Oral ganciclovir results in reduced CMV shedding in CMV-infected children. Acyclovir is not protective
against CMV.
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TABLE 12. Prophylaxis to prevent recurrence of opportunistic disease (after
chemotherapy for acute disease) in HIV-infected infants and children
Preventive Regimens
Pathogen Indication
I. Recommended for life as standard of care
Pneumocystis carinii Prior R carinii
pneumonia
First Choice
TMP-SMZ, 150/750
mg/m2/d in 2 divided
doses po t.i.w, on.
consecutive days (All)
Acceptable alternative
schedules for same
dosage: (All)
Single dose po t.i.w, on
consecutive days;
2 divided doses po q.d;
2 divided doses po
t.i.w, on alternate days
Alternative
Dapsone (children
aged >1 mo), 2 mg/kg
(max 100 mg) po q.d.
or 4 mg/kg (max
200 mg) po q.w. (CII);
aerosolized
pentamidine (children
aged >5 yrs), 300 mg
q.m. via Respirgard II
nebulizer (CIII);
atovaquone (aged
1-3 mo. and >24 mo.,
30 mg/kg po q.d.; aged
4-24 mo., 45 mg/kg po
q.d.) (CII)
Toxoplasma gondii* Prior toxoplasmic
encephalitis
Sulfadiazine,
85-120 mg/kg/d in
2-4 divided doses po
q.d. plus
pyrimethamine,
mg/kg or 15 mg/m2
(max 25 mg) po q.d.
plus leucovorin, 5 mg
po every 3 days (AI)
Clindamycin,
20-30 mg/kg/d in
4 divided doses po q.d.
plus pyrimethamine,
mg/kg po q.d. plus
leucovorin, 5 mg po
every 3 days (BI)
Mycobacterium avium Prior disease
complext
Clarithromycin,
7.5 mg/kg (max
500 mg) po b.i.d. (All)
plus ethambutol,
15 mg/kg (max
900 mg) po q.d. (All);
with or without
Azithromycin, 5 mg/kg
(max 250 mg) po q.d.
(All) plus ethambutol,
15 mg/kg (max
900 mg) po q.d. (All);
with or without
rifabutin, 5 mg/kg (max
rifabutin, 5 mg/kg (max 300 mg) po q.d. (CII)
300 mg) po q.d. (CII)
Cryptococcus
neoformans
Documented disease Fluconazole, 3-6 mg/kg
po q.d. (All)
Amphotericin B,
0.5-1.0 mg/kg iv
1-3x/week (AI);
itraconazole, 2-5
mg/kg po every 12-24h
(BII).
Histoplasma
capsulatum
Documented disease Itraconazole,
2-5 mg/kg po every
12-48 h (AIII)
Amphotericin B,
1.0 mg/kg iv q.w. (AIII)
Coccidioides immitis Documented disease Fluconazole, 6 mg/kg
po q.d. (AIII)
Amphotericin B,
1.0 mg/kg iv q.w. (AIII);
itraconazole,
2-5 mg/kg po every
12--48 h (AIII)
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TABLE 12. Prophylaxis to prevent recurrence of opportunistic disease (after
chemotherapy for acute disease) in, HIV-infected infants and children Continued
Pathogen
Cytomegal0virus
Preventive Regimens
Indication First Choice
Prior end-organ Ganciclovir, 5 mg/kg iv
disease q.d.; or foscarnet,
90-120 mg/kg iv q.d.
(AI)
Alternative
(For retinitis)
Ganciclovir
sustained-release
implant every 6-9 too.
plus ganciclovir,
30 mg/kg po t.i.d. (Bill)
Salmonella species
non-typh t)
Bacteremia TMP-SMZ, Antibiotic
150/750 mg/m2 in chemoprophylaxis
2 divided doses po q.d. with another active
for several months (CIII) agent (CIII)
II. Recommended only if subsequent episodes are frequent or severe
Invasive bacterial >2 infections in TMP-SMZ,
infections 1-year period 150/750 mg/m2, in
2 divided doses po q.d.
(BI); or IVIG, 400 mg/kg
every 2-4 wks. (BI)
Antibiotic
chemoprophylaxis
with another active
agent (Bill)
Herpes simplex virus Frequent/severe
recurrences
Acyclovir, 80 mg/kg/d
in 3-4 divided doses
po q.d. (All)
Candida
(oropharyngeal)
Frequent/severe
recurrences
Fluconazole, 3-6 mg/kg
po q.d. (CIII)
Candida (esophageal) Frequent/severe Fluconazole, 3-6 mg/kg Itraconazole solution,
recurrences po q.d. (Bill) 5 mg/kg po q.d. (CIII);
ketoconazole,
5-10 mg/kg po every
24-12h (CIII)
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA)
approval or approved labeling for the particular products or indications in question. Specifically, the terms
"safe" and "effective" might not be synonymous with the FDA-defined legal standards for product approval.
The Respirgard I1’" nebulizer is manufactured by Marquest, Englewood, Colorado. Letters and Roman
numerals in parentheses after regimens indicate the strength of the recommendations and the quality of
evidence supporting it (see Box, page 3).
ABBREVIATIONS: IVIG intravenous immune globulin; po by mouth; q.d. daily; q.m. monthly; q.w.
weekly; t.i.d. three times a day; t.i.w. three times a week; and TMP-SMZ trimethoprim-sulfamethoxazole.
* Only pyrimethamine plus sulfadiazine confers protection against PCP as well as toxoplasmosis. Although
the clindamycin plus pyrimethamine regimen is the preferred alternative in adults, it has not been tested
in children. However, these drugs are safe and are used for other infections.
tSignificant drug interactions might occur between rifabutin and protease inhibitors and nonnucleoside
reverse transcriptase inhibitorso Consult an expert.
Drug should be determined by susceptibilities of the organism isolated. Alternatives to TMP-SMZ include
ampicillin, chloramphenicol, or ciprofloxacin. However, ciprofloxacin is not approved for use in persons
aged <18 years; therefore, it should be used in children with caution and only if no alternatives exist.
Antimicrobial prophylaxis should be chosen based on the microorganism and antibiotic sensitivities. TMP-
SMZ, if used, should be administered daily. Providers should be cautious about using antibiotics solely for
this purpose because of the potential for development of drug-resistant microorganisms. IVIG might not
provide additional benefit to children receiving daily TMP-SMZ but may be considered for children who
have recurrent bacterial infections despite TMP-SMZ prophylaxis. Choice of antibiotic prophylaxis vs. IVIG
should also involve consideration of adherence, ease of intravenous access, and cost. If IVIG is used,
respiratory syncytial virus (RSV) IVIG (750 mg/kg), not monoclonal RSV antibody, may be substituted for
IVIG during the RSV season to provide broad antiinfective protection, if this product is available.
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TABLE 13. Criteria for discontinuing and restarting opportunistic infection prophylaxis
for adults with human immunodeficiency virus infection*
Criteria for Discontinuing Prophylaxis Criteria for Restarting
Opportunistic Illness Primary Secondary Prophylaxis
’/neumocystis carinii CD4+ >200 cells/lL for No criteria Same as criteria for
pneumonia >3-6 months (CII) recommended for initiating (CIII)
stopping
Disseminated CD4+ >100 cells/L for No criteria
Mycobacteriurn avium >3-6 months; recommended for
complex sustained suppression stopping
of HIV plasma RNA (CII)
Same as criteria for
initiating (CIII)
Toxoplasmosis No criteria No criteria
recommended for recommended for
stopping stopping
Not applicable
Cryptococcosis Not applicable No criteria
recommended for
stopping
Not applicable
Histoplasmosis Not applicable No criteria
recommended for
stopping
Not applicable
Coccidioidomycosis Not applicable No criteria
recommended for
stopping
Not applicable
Cytomegalovirus
retinitis
Not applicable CD4+ >100-150 Restart maintenance
cells/L for when CD4+
>3-6 months <50-100 cells/L (CIII).
Durable
suppression of HIV
plasma RNA
Nonsight-
threatening lesion
Adequate vision in
contralaterial eye
Regular
ophthalmic
examination (CIII)
The safety of discontinuing prophylaxis in children whose CD4+ counts have increased in
response to highly active antiretroviral therapy has not been studied.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 631999 USPHS/IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS
APPENDIX. Recommendations to Help Patients Avoid
Exposure to Opportunistic Pathogens*
SEXUAL EXPOSURES
1. Patients should use a latex condom during every act of sexual intercourse to
reduce the risk for acquiring cytomegalovirus, herpes simplex virus, and human papil-
Iomavirus, as well as other sexually transmitted pathogens (All). Condom use also
will, theoretically, reduce the risk foraCquiring human herpesvirus 8, as well as super-
infection with an HIV strain that has become resistant to antiretroviral drugs (Bill) and
will prevent transmission of HIV and other sexually transmitted pathogens to others
(All). Data regarding the use and efficacy of female condoms are incomplete, but these
devices should be considered as a risk-reduction strategy (Bill).
2. Patients should avoid sexual practices that might result in oral exposure to feces
(e.g., oral-anal contact) to reduce the risk for intestinal infections (e.g., crypto-
sporidiosis, shigellosis, campylobacteriosis, amebiasis, giardiasis, and hepatitis A and
B) (Bill).
INJECTION DRUG USE EXPOSURES
1. Injection drug use is a complex behavior that puts HIV-infected persons at risk for
hepatitis C virus infection, additional, possibly drug-resistant strains of HIV, and other
blood-borne pathogens. Providers should assess the individual’s readiness to change
this practice and encourage efforts to provide education and support directed at
recovery. Patients should be counseled to stop using injection drugs (AIII) and to enter
and complete substance-abuse treatment, including relapse prevention programs
(AIII).
2. If they are continuing to inject drugs, patients should be advised (Bill)
= to never reuse or share syringes, needles, water, or drug preparation equipment;
if, nonetheless, injection equipment that has been used by other persons is
shared, to first clean the equipment with bleach and water (U.S. Public Health
Service. HIV prevention bulletin" medical advice for persons who inject illicit
drugs. May 8, 1997. Rockville, Maryland: CDC, 1997);
to use only sterile syringes obtained from a reliable source (e.g., pharmacies or
syringe exchange programs);
to use sterile (e.g., boiled) water to prepare drugs; if not possible, to use clean
water from a reliable source (e.g., fresh tap water); to use a new or disinfected
container ("cooker") and a new filter ("cotton") to prepare drugs;
to clean the injection site with a new alcohol swab before injection;
to safely dispose of syringes after one use.
* I"ettes and Roman numerals in parentheses indicate the strength of the recommendation and
the quality of evidence supporting it (see Box, page 3).
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ENVIRONMENTAL AND OCCUPATIONAL EXPOSURES
1. Certain activities or types of employment might increase the risk for exposure to
tuberculosis (Bill). These include volunteer work or employment in health-care facili-
ties, correctional institutions, and shelters for the homeless, as well as other settings
identified as high risk by local health authorities. Decisions about whether to continue
with such activities should be made in conjunction with the health-care provider and
should be based on such factors as the patient’s specific duties in the workplace, the
prevalence of tuberculosis in the community, and the degree to which precautions
designed to prevent the transmission of tuberculosis are taken in the workplace (Bill).
These decisions will affect the frequency with which the patient should be screened
for tuberculosis.
2. Child-care providers and parents of children in child care are at increased risk for
acquiring CMV infection, cryptosporidiosis, and other infections (e.g., hepatitis A and
giardiasis) from children. The risk for acquiring infection can be diminished by good
hygienic practices, such as hand washing after fecal contact (e.g., during diaper
changing) and after contact with urine or saliva (All). All children in child-care facilities
also are at increased risk for acquiring these same infections; parents and other care-
takers of HIV-infected children should be advised of this risk (Bill).
3. Occupations involving contact with animals (e.g., veterinary work and employ-
ment in pet stores, farms, or slaughterhouses) might pose a risk for cryptosporidiosis,
toxoplasmosis, salmonellosis, campylobacteriosis, or Bartonella infection. However,
the available data are insufficient to justify a recommendation against work in such
settings.
4. Contact with young farm animals, especially animals with diarrhea, should be
avoided to reduce the risk for cryptosporidiosis (BII).
5. Hand washing after gardening or other contact with soil might reduce the risk for
cryptosporidiosis and toxoplasmosis (Bill).
6. In areas endemic for histoplasmosis, patients should avoid activities known to be
associated with increased risk (e.g., creating dust when working with surface soil;
cleaning chicken coops that are heavily contaminated with compost droppings;
disturbing soil beneath bird-roosting sites; cleaning, remodeling or demolishing old
buildings; and cave exploring) (CIII).
7. In areas endemic for coccidioidomycosis, when possible, patients should avoid
activities associated with increased risk, including those involving extensive exposure
to disturbed native soil (e.g., at building excavation sites or during dust storms) (CIII).
PET-RELATED EXPOSURES
Health-care providers should advise HIV-infected persons of the potential risk
posed by pet ownership. However, they should be sensitive to the possible psycho-
logical benefits of pet ownership and should not routinely advise HIV-infected persons
to part with their pets (Dill). Specifically, providers should advise HIV-infected patients
of the following precautions.
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General
1. Veterinary care should be sought when a pet develops diarrheal illness. If possi-
ble, HIV-infected persons should avoid contact with animals that have diarrhea (Bill).
A fecal sample should be obtained from animals with diarrhea and examined for Cryp-
tosporidium, Salmonella, and CampyIobacter.
2. When obtaining a new pet, HIV-infected patients should avoid animals aged
<6 months (or < 1 year for cats; see Cats section, which follows), especially those with
diarrhea (Bill). Because the hygienic and sanitary conditions in pet-breeding facilities,
pet stores, and animal shelters are highly variable, the patient should be cautious
when obtaining a pet from these sources. Stray animals should be avoided. Animals
aged <6 months, especially those with diarrhea, should be examined by a veterinarian
for Cryptosporidium, Salmonella, and CampyIobacter(BIII).
3. Patients should wash their hands after handling pets (especially before eating)
and avoid contact with pets’ feces to reduce the risk for cryptosporidiosis, salmonel-
Iosis, and campylobacteriosis (Bill). Hand washing for HIV-infected children should be
supervised.
Cats
4. Patients should be aware that cat ownership increases their risk for tooplas-
mosis and Bartonella infection, as well as enteric infections (CIII). Those who elect to
obtain a cat should adopt or purchase an animal that is aged >1 year and in good
health to reduce the risk for cryptosporidiosis, Bartonella infection, salmonellosis, and
campyIobacteriosis (BII).
5. Litter boxes should be cleaned daily, preferably by an HIV-negative, nonpregnant
person; if the HIV-infected patient performs this task, he or she should wash hands
thoroughly afterward to reduce the risk for toxoplasmosis (Bill).
6. To reduce the risk for toxoplasmosis, HIV-infected patients should keep cats
indoors, not allow them to hunt, and not feed them raw or undercooked meat (Bill).
7. Although declawing is not generally advised, patients should avoid activities that
might result in cat scratches or bites to reduce the risk for Bartonella infection (BII).
Patients should also wash sites of cat scratches or bites promptly (CIII) and should not
allow cats to lick the patients’ open cuts or wounds (Bill).
8. Care of cats should include flea control to reduce the risk for Bartonella infection
(CIII).
9. Testing cats for toxoplasmosis (Ell) or Bartonella infection (DII) is not recom-
mended.
Birds
10. Screening healthy birds for Cryptococcus neoformans, Mycobacterium avium,
or Histoplasma capsulatum is not recommended (Dill).
Other
11. Contact with reptiles (e.g., snakes, lizards, iguanas, and turtles) should be
avoided to reduce the risk for salmonellosis (Bill).
12. Gloves should be used during the cleaning of aquariums to reduce the risk for
infection with Mycobacterium marinum (Bill).
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13. Contact with exotic pets (e.g., nonhuman primates) should be avoided (CIII).
FOOD- AND WATER-RELATED EXPOSURES
1. Raw or undercooked eggs (including foods that might contain raw eggs [e.g.,
some preparations of hollandaise sauce, Caesar and certain other salad dressings,
and mayonnaise]); raw or undercooked poultry, meat, seafood; and unpasteurized
dairy products might contain enteric pathogens. Poultry and meat should be cooked
until no longer pink in the middle (internal temperature, >165 F [73.8 C]). Produce
should be washed thoroughly before being eaten (Bill).
2. Cross-contamination of foods should be avoided. Uncooked meats should not be
allowed to come in contact with other foods; hands, cutting boards, counters, and
knives and other utensils should be washed thoroughly after contact with uncooked
foods (Bill).
3. Although .the incidence of listeriosis is low, it is a serious disease that occurs
unusually frequently among HIV-infected persons who are severely immunosup-
pressed. Some soft cheeses and some ready-to-eat foods (e.g., hot dogs and cold cuts
from delicatessen counters) have been known to cause listeriosis. An HIV-infected per-
son who is severely immunosuppressed and who wishes to reduce the risk for
foodborne disease can prevent listeriosis by reheating these foods until they are
steaming before eating them (CIII).
4. Patients should not drink water directly from lakes or rivers because of the risk
for cryptosporidiosis and giardiasis (AIII). Waterborne infection might also result from
swallowing water during recreational activities. Patients should avoid swimming in
water that is likely to be contaminated with human or animal waste and should avoid
swallowing water during swimming (BII).
5. During outbreaks or in other situations in which a community "boil water advi-
sory" is issued, boiling water for 1 minute will eliminate the risk for acquiring
cryptosporidiosis (AI). Using submicron, personal-use water filters (home/office
types) and/or drinking bottled water might also reduce the risk (see Cryptosporidiosis
section in Disease-Specific Recommendations for information on personal-use filters
and bottled water) (CIII). Current data are inadequate to support a recommendation
that all HIV-infected persons boil or otherwise avoid drinking tap water in nonoutbreak
settings. However, persons who wish to take independent action to reduce their risk
for waterborne cryptosporidiosis may choose to take precautions similar to those rec-
ommended during outbreaks. Such decisions are best made in conjunction with a
health-care provider. Persons who opt for a personal-use filter or bottled water should
be aware of the complexities involved in selecting the appropriate products, the lack
of enforceable standards for destruction or removal of oocysts, the cost of the prod-
ucts, and the difficulty of using these products consistently. Patients taking
precautions to avoid acquiring cryptosporidiosis from drinking water should be
advised that ice made from contaminated tap water also can be a source of infection
(BII). Such persons should be aware that fountain beverages served in restaurants,
bars, theaters, and other public places might also pose a risk, because these bever-
ages, as well as the ice they might contain, are made from tap water. Nationally
distributed brands of bottled or canned carbonated soft drinks are safe to drink. Com-
mercially packaged noncarbonated soft drinks and fruit juices that do not require
refrigeration until after they are opened (i.e., those that can be stored unrefrigerated
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on grocery shelves) also are safe. Nationally distributed brands of frozen fruit juice
concentrate are safe if they are reconstituted by the user with water from a safe
source. Fruit juices that must be kept refrigerated from the time they are processed to
the time of consumption might be either fresh (unpasteurized) or heat-treated (pas-
teurized); only juices labeled as pasteurized should be considered free of risk from
Cryptosporidium. Other pasteurized beverages and beers are also considered safe to
drink (BII). No data are available concerning survival of Cryptosporidium oocysts in
wine.
TRAVEL-RELATED EXPOSURES
1. Travel, particularly to developing countries, might result in significant risks for
the exposure of HIV-infected persons to opportunistic pathogens, especially for
patients who are severely immunosuppressed. Consultation with health-care provid-
ers and/or with experts in travel medicine will help patients plan itineraries (Bill).
2. During travel to developing countries, HIV-infected persons are at even higher
risk for foodborne and waterborne infections than they are in the United States. Foods
and beverages in particular, raw fruits and vegetables, raw or undercooked seafood
or meat, tap water, ice made With tap water, unpasteurized milk and dairy products,
and items purchased from street vendors might be contaminated (All). Items that
are generally safe include steaming-hot foods, fruits that are peeled by the traveler,
bottled (especially carbonated) beverages, hot coffee or tea, beer, wine, and water
brought to a rolling boil for 1 minute (All). Treating water with iodine or chlorine might
not be as effective as boiling but can be used, perhaps in conjunction with filtration,
when boiling is not practical (Bill).
3. Waterborne infections might result from swallowing water during recreational
activities. To reduce the risk for cryptosporidiosis and giardiasis, patients should avoid
swallowing water during swimming and should not swim in water that might be con-
taminated (e.g., with sewage or animal waste) (BII).
4. Antimicrobial prophylaxis for traveler’s diarrhea is not recommended routinely
for HIV-infected persons traveling to developing countries (Dill). Such preventive ther-
apy can have adverse effects and can promote the emergence of drug-resistant
organisms. Nonetheless, several studies (none involving an HIV-infected population)
have shown that prophylaxis can reduce the risk for diarrhea among travelers (CDC.
Health information for international travel, 1999-2000. Atlanta, Georgia: U.S. Depart-
ment of Health and Human Services, 1999:202). Under selected circumstances (e.g.,
those in which the risk for infection is very high and the period of travel brief), the
provider and patient may weigh the potential risks and benefits and decide that anti-
biotic prophylaxis is warranted ((3111). For those persons to whom prophylaxis is
offered, fluoroquinolones (e.g., ciprofloxacin [500 mg daily]) can be considered (Bill),
although fluoroquinolones should not be given to children or pregnant women.
Trimethoprim-sulfamethoxazole (TMP-SMZ) (one double-strength tablet daily) also
has been shown to be effective, but resistance to this drug is now common in tropical
areas. Persons already taking TMP-SMZ for prophylaxis against Pneumocystis carinii
pneumonia (PCP) might gain some protection against traveler’s diarrhea. For HIV-in-
fected persons who are not already taking TMP-SMZ, health-care providers should be
cautious in prescribing this agent for prophylaxis of diarrhea because of the high rates
of adverse reactions and the possible need for the agent for other purposes (e.g., PCP
prophylaxis) in the future.
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5. All HIV-infected travelers to developing countries should carry a sufficient supply
of an antimicrobial agent to be taken empirically should diarrhea develop (Bill). One
appropriate regimen is 500 mg of ciprofloxacin twice a day for 3-7 days. Alternative
antibiotics (e.g., TMP-SMZ) should be considered as empirical therapy for use by chil-
dren and pregnant women (CIII). Travelers should consult a physician if their diarrhea
is severe and does not respond to empirical therapy, if their stools contain blood, if
fever is accompanied by shaking chills, or if dehydration develops. Antiperistaltic
agents (e.g., diphenoxylate and Ioperamide) are used for the treatment of diarrhea;
however, they should not be used by patients with high fever or with blood in the
stool, and their use should be discontinued if symptoms persist beyond 48 hours (All).
Antiperistaltic agents are not recommended for children (Dill).
6. Travelers should be advised about other preventive measures appropriate for
anticipated exposures (e.g., chemoprophylaxis for malaria, protection against arthro-
pod vectors, treatment with immune globulin, and vaccination) (All). They should
avoid direct contact of the skin with soil or sand (e.g., by wearing shoes and protective
clothing and using towels on beaches) in areas where fecal contamination of soil is
likely (Bill).
7. In general, live-virus vaccines should be avoided (Ell). One exception is measles
vaccine, which is recommended for nonimmune persons. However, measles vaccine
is not recommended for persons who are severely immunosuppressed (Dill); immune
globulin should be considered for measles-susceptible, severely immunosuppressed
persons who are anticipating travel to measles-endemic countries (Bill). Another
exception is varicella vaccine, which may be administered to asymptomatic nonim-
munosuppressed children (BII). Inactivated (killed) poliovirus vaccine should be used
instead of oral (live) poliovirus vaccine, which is contraindicated for HIV-infected per-
sons. Persons at risk for exposure to typhoid fever should be administered an
inactivated parenteral typhoid vaccine instead of the live attenuated oral preparation.
Yellow fever vaccine is a live-virus vaccine with uncertain safety and efficacy in HIV-
infected persons. Travelers with asymptomatic HIV infection who cannot avoid poten-
tial exposure to yellow fever should be offered the choice of vaccination. If travel to a
zone with yellow fever is necessary and vaccination is not administered, patients
should be advised of the risk, instructed in methods for avoiding the bites of vector
mosquitoes, and provided with a vaccination waiver letter.
8. In general, killed vaccines (e.g., diphtheria-tetanus, rabies, hepatitis A, Japanese
encephalitis vaccines) should be used for HIV-infected persons just as they would be
used for non-HIV-infected persons anticipating travel (Bill). Preparation for travel
should include a review and updating of routine vaccinations, including diphtheria-
tetanus for adults and all routine immunizations for children. The currently available
cholera vaccine is not recommended for persons following a usual tourist itinerary,
even if travel includes countries reporting cases of cholera (DII).
9. Travelers should be informed about other area-specific risks and instructed in
ways to reduce those risks (Bill). Geographically focal infections that pose a high risk
to HIV-infected persons include visceral leishmaniasis (a protozoan infection transmit-
ted by the sandfly) and several fungal infections (e.g., Penicillium marneffei infection,
coccidioidomycosis, and histoplasmosis). Many tropical and developing areas have
high rates of tuberculosis.
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